




B3

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : C12N 15/19, C07K 13/00 A61K 37/02		A1	(11) International Publication Number: WO 93/23541 (43) International Publication Date: 25 November 1993 (25.11.93)
(21) International Application Number: PCT/US93/04648 (22) International Filing Date: 17 May 1993 (17.05.93) (30) Priority data: 07/884,811           18 May 1992 (18.05.92)   US 07/885,971           18 May 1992 (18.05.92)   US (60) Parent Applications or Grants (63) Related by Continuation US                   07/884,811 (CIP) Filed on           18 May 1992 (18.05.92) US                   07/885,971 (CIP) Filed on           18 May 1992 (18.05.92) (71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only): GODOWSKI, Paul, J. [US/US]; 305 Loma Vista Terrace, Pacifica, CA 94044 (US). LOKKER, Nathalie, A. [FR/US]; 741 40th Avenue, San Francisco, CA 94121 (US). MARK, Melanie, R. [US/US]; 1548 Hudson Street, #204, Redwood City, CA 94061 (US). (74) Agents: DREGER, Ginger, R. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: HEPATOCYTE GROWTH FACTOR VARIANTS



## (57) Abstract

The invention concerns hepatocyte growth factor (HGF) amino acid sequence variants. The preferred variants are resistant to proteolytic cleavage by enzymes capable of *in vivo* conversion of HGF into its two-chain form and/or contain a mutation within the protease domain of HGF.

J1017 U.S. PRO

10/081309

02/21/02

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

HEPATOCYTE GROWTH FACTOR VARIANTSBACKGROUND OF THE INVENTIONI. Field of the Invention

5       The present invention concerns amino acid sequence variants of hepatocyte growth factor (HGF), methods and means for preparing such variants, and pharmaceutical compositions comprising them.

II. Description of Background and Related Art

10       HGF was identified initially as a mitogen for hepatocytes [Michalopoulos *et al.*, Cancer Res. **44**, 4414-4419 (1984); Russel *et al.*, J. Cell. Physiol. **119**, 183-192 (1984) and Nakamura *et al.*, Biochem. Biophys. Res. Comm. **122**:1450-1459 (1984)]. Nakamura *et al.*, *Supra* reported the purification of HGF from the serum of partially  
15       hepatectomized rats. Subsequently, HGF was purified from rat platelets, and its subunit structure was determined [Nakamura *et al.*, Proc. Natl. Acad. Sci. USA, **83**, 6489-6493 (1986); and Nakamura *et al.*, FEBS Letters **224**, 311-316 (1987)]. The purification of human HGF (huHGF) from human plasma was first described by Gohda *et al.*, *J.*  
20       Clin. Invest. **81**, 414-419 (1988).

      Both rat HGF and huHGF have been molecularly cloned, including the cloning and sequencing of a naturally occurring variant lacking 5 amino acids designated "delta5 HGF" [Miyazawa *et al.*, Biochem. Biophys. Res. Comm. **163**, 967-973 (1989); Nakamura *et al.*, Nature **342**,  
25       440-443 (1989); Seki *et al.*, Biochem. and Biophys. Res. Commun. **172**, 321-327 (1990); Tashiro *et al.*, Proc. Natl. Acad. Sci. USA **87**, 3200-3204 (1990); Okajima *et al.*, Eur. J. Biochem. **193**, 375-381 (1990)].

      The mature form of huHGF, corresponding to the major form purified from human serum, is a disulfide linked heterodimer derived  
30       by proteolytic cleavage of the human pro-hormone between amino acids R494 and V495. This cleavage process generates a molecule composed of an  $\alpha$ -subunit of 440 amino acids ( $M_r$  69 kDa) and a  $\beta$ -subunit of 234 amino acids ( $M_r$  34 kDa). The nucleotide sequence of the hHGF cDNA reveals that both the  $\alpha$ - and the  $\beta$ -chains are contained in a single  
35       open reading frame coding for a pre-pro precursor protein. In the predicted primary structure of mature hHGF, an interchain S-S bridge is formed between Cys 487 of the  $\alpha$ -chain and Cys 604 in the  $\beta$ -chain (see Nakamura *et al.*, Nature, *supra*). The N-terminus of the  $\alpha$ -chain

is preceded by 54 amino acids, starting with a methionine group. This segment includes a characteristic hydrophobic leader (signal) sequence of 31 residues and the prosequence. The  $\alpha$ -chain starts at amino acid (aa) 55, and contains four Kringle domains. The so called "hairpin domain" includes amino acid residues 70-96 of wild-type human HGF. The Kringle 1 domain extends from about aa 128 to about aa 206, the Kringle 2 domain is between about aa 211 and about aa 288, the Kringle 3 domain is defined as extending from about aa 303 to about aa 383, and the Kringle 4 domain extends from about aa 391 to about aa 464 of the  $\alpha$ -chain. It will be understood that the definition of the various Kringle domains is based on their homology with kringle-like domains of other proteins (prothrombin, plasminogen), therefore, the above limits are only approximate. As yet, the function of these Kringles has not been determined. The  $\beta$ -chain of huHGF shows high homology to the catalytic domain of serine proteases (38% homology to the plasminogen serine protease domain). However, two of the three residues which form the catalytic triad of serine proteases are not conserved in huHGF. Therefore, despite its serine protease-like domain, hHGF appears to have no proteolytic activity and the precise role of the  $\beta$ -chain remains unknown. HGF contains four putative glycosylation sites, which are located at positions 294 and 402 of the  $\alpha$ -chain and at positions 566 and 653 of the  $\beta$ -chain.

In a portion of cDNA isolated from human leukocytes in-frame deletion of 15 base pairs was observed. Transient expression of the cDNA sequence in COS-1 cells revealed that the encoded HGF molecule (delta5 HGF) lacking 5 amino acids in the Kringle 1 domain was fully functional (Seki *et al.*, *supra*).

A naturally occurring huHGF variant has recently been identified which corresponds to an alternative spliced form of the huHGF transcript containing the coding sequences for the N-terminal finger and first two kringle domains of mature huHGF [Chan *et al.*, *Science* 254, 1382-1385 (1991); Miyazawa *et al.*, *Eur. J. Biochem.* 197, 15-22 (1991)]. This variant, designated HGF/NK2, has been proposed to be a competitive antagonist of mature huHGF.

The comparison of the amino acid sequence of rat HGF with that of huHGF revealed that the two sequences are highly conserved and have the same characteristic structural features. The length of the four Kringle domains in rat HGF is exactly the same as in huHGF.



Furthermore, the cysteine residues are located in exactly the same positions; an indication of similar three-dimensional structures (Okajima *et al.*, *supra*; Tashiro *et al.*, *supra*).

The HGF receptor has been identified as the product of the c-Met  
5 proto-oncogene [Bottaro *et al.*, *Science* **251**, 802-804 (1991); Naldini  
*et al.*, *Oncogene* **6**, 501-504 (1991)], an 190-kDa heterodimeric (a  
disulfide-linked 50-kDa  $\alpha$ -chain and a 145-kDa  $\beta$ -chain) membrane-  
spanning tyrosine kinase protein [Park *et al.*, *Proc. Natl. Acad. Sci.*  
*USA* **84**, 6379-6383 (1987)]. The c-Met protein becomes phosphorylated on  
10 tyrosine residues of the 145-kDa  $\beta$ -subunit upon HGF binding.

The levels of HGF increase in the plasma of patients with hepatic  
failure (Gohda *et al.*, *supra*) and in the plasma [Lindroos *et al.*,  
*Hepatol.* **13**, 734-750 (1991)] or serum [Asami *et al.*, *J. Biochem.* **109**,  
8-13 (1991)] of animals with experimentally induced liver damage. The  
15 kinetics of this response is rapid, and precedes the first round of  
DNA synthesis during liver regeneration suggesting that HGF may play a  
key role in initiating this process. More recently, HGF has been  
shown to be a mitogen for a variety of cell types including  
melanocytes, renal tubular cells, keratinocytes, certain endothelial  
20 cells and cells of epithelial origin [Matsumoto *et al.*, *Biochem.*  
*Biophys. Res. Commun.* **176**, 45-51 (1991); Igawa *et al.*, *Biochem.*  
*Biophys. Res. Commun.* **174**, 831-838 (1991); Han *et al.*, *Biochem.* **30**,  
9768-9780 (1991); Rubin *et al.*, *Proc. Natl. Acad. Sci. USA* **88**, 415-419  
(1991)]. Interestingly, HGF can also act as a "scatter factor", an  
25 activity that promotes the dissociation of epithelial and vascular  
endothelial cells in vitro [Stoker *et al.*, *Nature* **327**, 239-242 (1987);  
Weidner *et al.*, *J. Cell Biol.* **111**, 2097-2108 (1990); Naldini *et al.*,  
*EMBO J.* **10**, 2867-2878 (1991)]. Moreover, HGF has recently been  
described as an epithelial morphogen [Montesano *et al.*, *Cell* **67**, 901-  
30 908 (1991)]. Therefore, HGF has been postulated to be important in  
tumor invasion and in embryonic development. Chronic c-Met/HGF  
receptor activation has been observed in certain malignancies [Cooper  
*et al.*, *EMBO J.* **5**, 2623 (1986); Giordano *et al.*, *Nature* **339**, 155  
(1989)].

35 It would be desirable to better understand the structure-activity  
relationship of HGF in order to identify functionally important  
domains in the HGF amino acid sequence.

It would be particularly desirable to identify the amino acid residues which are responsible for the interaction of HGF with its receptor.

5 It would be also desirable to identify the amino acid residues which are responsible for HGF biological activity.

It would further be desirable to provide amino acid sequence variants of HGF that have altered (preferably enhanced) receptor binding affinity as compared to the corresponding mature, wild-type HGF.

10 It would also be desirable to provide HGF amino acid sequence variants which have retained or enhanced receptor binding affinity as compared to the corresponding wild-type HGF, but are substantially devoid of HGF biological activity. Such molecules could act as competitive antagonists of HGF action.

15 It would further be desirable to provide HGF amino acid sequence variants that have retained or enhanced receptor binding affinity and increased biological activity as compared to the corresponding wild-type HGF (HGF agonists). Accordingly, it is an object of the present invention to provide HGF variants having retained or improved  
20 the receptor binding affinity of the corresponding mature wild-type HGF. It is another object of the invention to provide HGF variants that have retained substantially full receptor binding affinity of the corresponding mature wild-type HGF and are substantially incapable of HGF receptor activation. It is a further  
25 object to provide HGF variants that have retained substantially full receptor binding affinity of the corresponding mature wild-type HGF and have improved biological properties.

These and further objects will be apparent to one of ordinary skill in the art.

30

#### SUMMARY OF THE INVENTION

The foregoing objects are achieved by the provision of HGF variants having amino acid alterations within various domains of the wild-type HGF amino acid sequence.

35 In one aspect, HGF variants are provided that are resistant to proteolytic cleavage by enzymes that are capable of in vivo conversion of HGF into its two-chain form. The variants are preferably stabilized in single-chain form by site directed mutagenesis within a

region recognized by an enzyme capable of converting HGF into its two-chain form.

5 In a particular embodiment, such variants have an amino acid alteration at or adjacent to amino acid positions 493, 494, 495 or 496 of the wild-type huHGF amino acid sequence. The alteration preferably is the substitution of at least one amino acid at amino acid positions 493-496 of the wild-type huHGF amino acid sequence.

10 In another embodiment, the variants retain substantially full receptor binding affinity of the corresponding wild-type HGF and are substantially incapable of HGF receptor activation. HGF variants with enhanced receptor binding affinity and substantially lacking the ability to activate the HGF receptor are particularly preferred. Such compounds are competitive antagonists of the corresponding wild-type HGF and, when present in sufficient concentration, are capable of  
15 inhibiting the binding of their wild-type counterparts to their ligands.

In another aspect, here are provided HGF variants having an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the  
20 corresponding wild-type HGF.

In a specific embodiment, these variants have substantially retained or improved receptor binding affinity as compared to the corresponding wild-type HGF, and are substantially devoid of HGF biological activity. Such compounds, if present in sufficient  
25 concentration, will act as competitive antagonists of HGF action.

In another specific embodiment, the variants combine substantially retained or improved receptor binding affinity with improved biological activity, as compared to the corresponding wild-type HGF. Such variants are valuable as HGF agonists.

30 In a preferred embodiment, the HGF variants within this group comprise an alteration in a region corresponding to the catalytic site of serine proteases. More preferably the alteration is at or adjacent to any of positions 534, 673 and 692 of the wild-type human HGF (huHGF) amino acid sequence.

35 The alteration preferably is substitution.

In a particularly preferred embodiment, at least two of the residues at amino acid positions 534, 673 and 692 of the wild-type huHGF sequence are replaced by another amino acid.

In a preferred group of the HGF variants herein, both tyrosine (Y) at position 673 and valine (V) at position 692 of the huHGF sequence are replaced by another amino acid. This alteration potentially yields HGF variants which substantially retain the receptor binding affinity of wild-type huHGF but are substantially devoid of HGF biological activity.

The mutations around the one-chain to two-chain cleavage site and within the protease domain may be advantageously combined for improved biological properties.

Variants with increased receptor binding affinity as compared to the corresponding wild-type HGF are particularly preferred. The increase in receptor binding affinity may, for example, be accomplished by an alteration in the receptor-binding domain of the wild-type HGF amino acid sequence, and preferably within the Kringle 1 domain.

Kringle 1 variants with amino acid alterations within the patch defined by amino acid positions 159, 161, 195 and 197, or at amino acid position 173 of the wild-type huHGF amino acid sequence are particularly preferred, but other positions within the Kringle 1 domain have also been identified as having a genuine effect on the receptor binding properties and/or the specific activity of HGF.

Furthermore, amino acid sequence variants with alterations at amino acid positions preceding the Kringle 1 domain, in particular those just N- or C-terminal to the hairpin domain, have been found to have significantly different binding properties and biological activity from those of the corresponding wild-type HGF.

The variants of this invention may be devoid of functional Kringle 2 and/or Kringle 3 and/or Kringle 4 domains.

In all embodiments, huHGF amino acid sequence variants are preferred.

In other embodiments, the invention relates to DNA sequences encoding the variants described above, replicable expression vectors containing and capable of expressing such DNA sequences in a transformed host cell, transformed host cells, and a process comprising culturing the host cells so as to express the DNAs encoding the HGF variants.

In yet another embodiment, the invention relates to therapeutic compositions comprising HGF variants having HGF agonist or antagonist properties.

#### BRIEF DESCRIPTION OF THE DRAWINGS

5        Figure 1 is a schematic representation of the  $\alpha$ - and  $\beta$ -subunits of huHGF. Shown in the  $\alpha$ -chain are the signal sequence (boxed region) which encompasses amino acids 1 - 31, the predicted finger and four Kringle domains, each with their respective three disulfide bonds. The cleavage site for generation of the heterodimeric  $\alpha/\beta$  form of huHGF  
10 immediately follows the P1 cleavage residue R494. This last residue has been specifically substituted with either E, D or A to generate HGF single-chain variants. The  $\beta$ -chain, which follows the cleavage site, contains homology to serine proteases. It is proposed that the  $\alpha$ - and  $\beta$ -chains are held together by a unique disulfide-bridge between  
15 C487( $\alpha$ ) and C604( $\beta$ ) (Nakamura et al., 1989, *supra*). Three residues within the  $\beta$ -chain have been substituted individually or in combination to reconstitute the authentic residues of a serine-protease. Schematic representations of the mature forms of the C-terminal truncation variants are depicted below: N-207, deleted after  
20 the first Kringle; N-303, deleted after the second Kringle; N-384, deleted after the third Kringle and the  $\alpha$ -chain. Also shown are the variants where deletions of each of the Kringles ( $\Delta K1$ ,  $\Delta K2$ ,  $\Delta K3$  and  $\Delta K4$ ) were introduced. In each case, the deletions specifically remove the entire Kringle from C1 to C6.

25        Figure 2 shows the results of Western blot of wild-type rhuHGF and single-chain variants. Conditioned media from mock transfected 293 cells or stable 293 cells expressing either wild-type rhuHGF (WT) or the variants R494E, R494A or R494D were fractionated under reducing conditions on an 8% sodium-dodecyl sulfate-polyacrylamide gel and  
30 blotted. The blot was reacted with polyclonal anti-HGF antisera which recognizes epitopes primarily in the  $\alpha$ -chain. Molecular masses (kilodaltons) of the marker are as indicated. Also indicated are the positions of the  $\alpha$ -chain and uncleaved single-chain forms of huHGF. Note that the polyclonal antibody cross-reacts with an unidentified  
35 band (\*) present even in the control transfected 293 cells, which do not express detectable quantities of huHGF.

Figure 3: Mitogenic activity (A) and competitive receptor binding (B) of wild-type (WT) rhuHGF and single-chain variants. (A) Biological

activity was determined by the ability of WT rhuHGF and variants to induce DNA synthesis of rat hepatocytes in primary culture as described in Example 2. Shown are the mean cpm from duplicates in a representative assay. Mock supernatant from control cells did not stimulate DNA synthesis in these cells (no cpm increase above background levels). (B) To perform competitive binding, various dilutions of supernatants of human 293 cells containing wt rhuHGF or variants were incubated with 50 pM of the huHGF receptor-IgG fusion protein as described in Example 2. Data represent inhibition of binding as the percentage of any competing ligand from a representative experiment and were corrected by subtraction of background values from control 293 cells.

Figure 4: Western blot of ligand-induced tyrosine-phosphorylation on the 145 kDa  $\beta$ -subunit of the HGF receptor by wild-type rhuHGF, single-chain or protease domain huHGF variants. Lysates from A549 cells incubated for 5 minutes without (-) or with 200 ng/mL of purified wt rhuHGF (WT), single-chain (R494E) or double protease variants (Y673S,V692S) were prepared and immunoprecipitated with an anti-HGF receptor antibody and blotted with anti-phosphotyrosine antibodies. Molecular masses (kilodaltons) are as indicated.

Figure 5 depicts the nucleotide sequence encoding the plasmid pRK5.1 (SEQ. ID. NO: 1).

Figure 6 depicts the nucleotide sequence encoding the plasmid p.CIS.EBON (SEQ. ID. NO: 15).

#### DETAILED DESCRIPTION OF THE INVENTION

##### I. Definitions

As used herein, the terms "hepatocyte growth factor", "HGF" and "huHGF" refer to a (human) growth factor capable of specific binding to a receptor of wild-type (human) HGF, which growth factor typically has a structure with six domains (finger, Kringle 1, Kringle 2, Kringle 3, Kringle 4 and serine protease domains), but nonetheless may have fewer domains or may have some of its domains repeated if it still retains its qualitative HGF receptor binding ability. This definition specifically includes the delta5 huHGF as disclosed by Seki et al., *supra*. The terms "hepatocyte growth factor" and "HGF" also include hepatocyte growth factor from any non-human animal species, and in particular rat HGF.

The terms "wild-type human hepatocyte growth factor", "native human hepatocyte growth factor", "wild-type huHGF", and "native huHGF" refer to native sequence human HGF, i.e., that encoded by the cDNA sequence published by Miyazawa, *et al.* 1989, *supra*, or Nakamura *et al.*, 1989, *supra*, including its mature, pre, pre-pro, and pro forms, purified from natural source, chemically synthesized or recombinantly produced. The sequences reported by Miyazawa *et al.* and Nakamura *et al.* differ in 14 amino acids. The reason for the differences is not entirely clear; polymorphism or cloning artifacts are among the possibilities. Both sequences are specifically encompassed by the foregoing terms as defined for the purpose of the present invention. It will be understood that natural allelic variations exist and can occur among individuals, as demonstrated by one or more amino acid differences in the amino acid sequence of each individual. Amino acid positions in the variant huHGF molecules herein are indicated in accordance with the numbering of Miyazawa *et al.* 1989, *supra*.

The terms "(HGF) biological activity", "biologically active", "activity" and "active" refer to any mitogenic, motogenic or morphogenic activities exhibited by wild-type human HGF. The HGF biological activity may, for example, be determined in an *in vitro* or *in vivo* assay of hepatocyte growth promotion. Adult rat hepatocytes in primary culture have been extensively used to search for factors that regulate hepatocyte proliferation. Accordingly, the mitogenic effect of an HGF variant can be conveniently determined in an assay suitable for testing the ability of an HGF molecule to induce DNA synthesis of rat hepatocytes in primary cultures, such as, for example, described in Example 2. Human hepatocytes are also available from whole liver perfusion on organs deemed unacceptable for transplantation, pare-downs of adult livers used for transplantation in children, fetal livers and liver remnants removed at surgery for other indications. Human hepatocytes can be cultured similarly to the methods established for preparing primary cultures of normal rat hepatocytes. Hepatocyte DNA synthesis can, for example, be assayed by measuring incorporation of [<sup>3</sup>H]thymidine into DNA, with appropriate hydroxyurea controls for replicative synthesis.

The effect of HGF variants on hepatocyte growth can also be tested *in vivo* in animal models of liver dysfunction and regeneration, such as in rats following partial hepatectomy, or carbon tetrachloride

caused hepatic injury, in D-galactosamine induced acute liver failure models, etc. According to a suitable protocol, a liver poison, e.g.  $\alpha$ -naphthylisothiocyanate (ANIT) is administered to rats in a predetermined concentration capable of causing reproducible

5 significant elevation of liver enzyme and bilirubin levels. The rats are then treated with the HGF variant to be tested, sacrificed and the liver enzyme and bilirubin levels are determined. The livers are additionally observed for hepatic lesions.

The expression "retaining substantially full receptor binding

10 affinity of wild-type (hu)HGF" and grammatical variant thereof as used herein mean that the receptor binding affinity of the HGF variant is not less than about 70%; preferably not less than about 80%, more preferably not less than about 90%, most preferably not less than about 95% of the affinity with which wild-type (hu)HGF binds its

15 native receptor.

The terms "substantially incapable of HGF receptor activation" and "substantially devoid of HGF biological activity" mean that the activity exhibited by an HGF variant is less than about 20%, preferably less than about 15%, more preferably less than about 10%,

20 most preferably less than about 5% of the respective activity of wild-type (human) HGF in an established assay of receptor activation or HGF biological activity, as hereinabove defined.

The terms "amino acid" and "amino acids" refer to all naturally occurring L- $\alpha$ -amino acids. This definition is meant to include

25 norleucine, ornithine, and homocysteine. The amino acids are identified by either the single-letter or three-letter designations:

Asp	D	aspartic acid	Ile	I	isoleucine
Thr	T	threonine	Leu	L	leucine
Ser	S	serine	Tyr	Y	tyrosine
30 Glu	E	glutamic acid	Phe	F	phenylalanine
Pro	P	proline	His	H	histidine
Gly	G	glycine	Lys	K	lysine
Ala	A	alanine	Arg	R	arginine
Cys	C	cysteine	Trp	W	tryptophan
35 Val	V	valine	Gln	Q	glutamine
Met	M	methionine	Asn	N	asparagine

These amino acids may be classified according to the chemical composition and properties of their side chains. They are broadly



## I. Charged Amino Acids

## II. Uncharged Amino Acids

10      Aliphatic Residues: glycine, alanine, valine, leucine,  
                isoleucine

Aromatic Residues: phenylalanine, tyrosine, tryptophan

Substitutional HGF variants are those that have at least one amino acid residue in the corresponding wild-type HGF sequence removed and a different amino acid inserted in its place at the same position. The substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more amino acids have been substituted in the same molecule.

Moderate changes in the activity of the HGF molecule would be expected by substituting an amino acid with a side chain that is similar in charge and/or structure to that of the native molecule. This type of substitution, referred to as a conservative substitution, would not be expected to substantially alter either the structure of

the polypeptide backbone or the charge or hydrophobicity of the molecule in the area of the substitution.

Insertional HGF variants are those with one or more amino acids inserted immediately adjacent to an amino acid at a particular position in the wild-type HGF molecule. Immediately adjacent to an amino acid means connected to either the  $\alpha$ -carboxy or  $\alpha$ -amino functional group of the amino acid. The insertion may be one or more amino acids. Ordinarily, the insertion will consist of one or two conservative amino acids. Amino acids similar in charge and/or structure to the amino acids adjacent to the site of insertion are defined as conservative. Alternatively, this invention includes insertion of an amino acid with a charge and/or structure that is substantially different from the amino acids adjacent to the site of insertion.

Deletional variants are those with one or more amino acids in the wild-type HGF molecule removed. Ordinarily, deletional variants will have one or two amino acids deleted in a particular region of the HGF molecule.

The notations used throughout this application to describe huHGF amino acid sequence variants are described below. The location of a particular amino acid in the polypeptide chain of huHGF is identified by a number. The number refers to the amino acid position in the amino acid sequence of the mature, wild-type human HGF polypeptide as disclosed in Miyazawa *et al.*, 1989, *supra*. In the present application, similarly positioned residues in huHGF variants are designated by these numbers even though the actual residue number is not so numbered due to deletions or insertions in the molecule. This will occur, for example, with site-directed deletional or insertional variants. The amino acids are identified using the one-letter code. Substituted amino acids are designated by identifying the wild-type amino acid on the left side of the number denoting the position in the polypeptide chain of that amino acid, and identifying the substituted amino acid on the right side of the number.

For example, replacement of the amino acid arginine (R) by glutamic acid (E) at amino acid position 494 of the wild-type huHGF molecule yields a huHGF variant designated R494E huHGF. Similarly, the huHGF variant obtained by substitution of serine (S) for tyrosine (Y) at amino acid position 673 and serine (S) for valine (V) at amino

acid position 692 of the wild-type huHGF molecule is designated Y673S,V692S huHGF.

Deletional variants are identified by indicating the amino acid residue and position at either end of the deletion, inclusive, and placing the Greek letter delta, " $\Delta$ ", to the left of the indicated amino acids. Deletion of a single amino acid is indicated by placing  $\Delta$  to the left of the single letter code and number indicating the position of the deleted amino acid.

Insertional variants are designated by the use of brackets "[]" around the inserted amino acids, and the location of the insertion is denoted by indicating the position of the amino acid on either side of the insertion.

The alterations in the amino acid sequence of the HGF variants herein are indicated with reference to amino acid positions in the wild-type human HGF amino acid sequence. (Miyazawa *et al.*, *supra*). Methods for the alignment of homologous amino acid sequences from various species are well known in the art.

The terms "DNA sequence encoding", "DNA encoding" and "nucleic acid encoding" refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide chain. The DNA sequence thus codes for the amino acid sequence.

The terms "replicable expression vector" and "expression vector" refer to a piece of DNA, usually double-stranded, which may have inserted into it a piece of foreign DNA. Foreign DNA is defined as heterologous DNA, which is DNA not naturally found in the host cell. The vector is used to transport the foreign or heterologous DNA into a suitable host cell. Once in the host cell, the vector can replicate independently of the host chromosomal DNA, and several copies of the vector and its inserted (foreign) DNA may be generated. In addition, the vector contains the necessary elements that permit translating the foreign DNA into a polypeptide. Many molecules of the polypeptide encoded by the foreign DNA can thus be rapidly synthesized.

In the context of the present invention the expressions "cell", "cell line", and "cell culture" are used interchangeably, and all such designations include progeny.

The terms "transformed (host) cell" , "transformant" and "transformed" refer to the introduction of DNA into a cell. The cell is termed a "host cell". The introduced DNA is usually in the form of a vector containing an inserted piece of DNA. The introduced DNA sequence may be from the same species as the host cell or a different species from the host cell, or it may be a hybrid DNA sequence, containing some foreign and some homologous DNA. The words transformants and transformed (host) cells include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological property as screened for in the originally transformed cell are included.

The technique of "polymerase chain reaction" or "PCR", as used herein, generally refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Patent No. 4,683,195, issued 28 July 1987 and in Current Protocols in Molecular Biology, Ausubel et al. eds., Greene Publishing Associates and Wiley-Interscience 1991, Volume 2, Chapter 15.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies. The monoclonal antibodies include hybrid and recombinant antibodies produced by splicing a variable (including hypervariable) domain of an anti-selectin ligand antibody with a constant domain (e.g. "humanized" antibodies), only one of which is directed against a selectin, or a light chain with a heavy chain, or a chain from one species with a chain from another species, or fusions with heterologous proteins, regardless of species of origin or immunoglobulin class or subclass designation, as well as antibody fragments (e.g., Fab, F(ab')<sub>2</sub>, and Fv). Cabilly, et al., U.S. Pat. No. 4,816,567; Mage & Lamoyi, in Monoclonal Antibody Production Techniques and Applications, pp.79-97 (Marcel Dekker, Inc., New York,

1987). Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from such a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.

5 The term "immunoglobulin" generally refers to polypeptides comprising a light or heavy chain usually both disulfide bonded in the native "Y" configuration, although other linkage between them, including tetramers or aggregates thereof, is within the scope hereof.

10 Immunoglobulins (Ig) and certain variants thereof are known and many have been prepared in recombinant cell culture. For example, see U.S. Patent 4,745,055; EP 256,654; Faulkner *et al.*, Nature 298:286 (1982); EP 120,694; EP 125,023; Morrison, J. Immun. 123:793 (1979); Köhler *et al.*, Proc. Nat'l. Acad. Sci. USA 77:2197 (1980); Raso *et al.*, Cancer Res. 41:2073 (1981); Morrison *et al.*, Ann. Rev. Immunol. 2:239 (1984); Morrison, Science 229:1202 (1985); Morrison *et al.*, Proc. Nat'l. Acad. Sci. USA 81:6851 (1984); EP 255,694; EP 266,663; and WO 88/03559. Reassorted immunoglobulin chains also are known. See for example U.S. patent 4,444,878; WO 88/03565; and EP 68,763 and  
15 20 references cited therein. The immunoglobulin moiety in the chimeras of the present invention may be obtained from IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, or IgG<sub>4</sub> subtypes, IgA, IgE, IgD or IgM, but preferably IgG<sub>1</sub> or IgG<sub>3</sub>.

## II. Selection of the HGF Variants

25 The present invention is based upon the study of structure-activity and structure-receptor binding relationship in amino acid sequence variants of HGF.

Certain HGF variants of the present invention are resistant to proteolytic cleavage by enzymes that are capable of in vivo conversion  
30 of the single-chain HGF proenzyme into its two-chain form. Such enzymes are trypsin-like proteases. Absent alterations, the proteolytic cleavage takes place between Arg494 and Val495 of the wild-type huHGF sequence. The resistance to proteolytic cleavage is preferably achieved by site-directed mutagenesis within a region  
35 recognized by an enzyme capable of converting HGF into its two-chain form, and preferably within the Leu-Arg-Val-Val (LRVV) sequence at amino acid residues 493-496 of the wild-type huHGF sequence. The variants herein may, for example, contain single or multiple amino

acid substitutions, insertions or deletions at or adjacent to amino acid positions 493, 494, 495 and 496 in the wild-type human HGF amino acid sequence.

5 A preferred alteration is the replacement of arginine at amino acid position 494 with any other amino acid, preferably glutamic acid, aspartic acid or alanine. In general, the substitution of smaller, apolar or acidic amino acids for arginine at this position is believed to yield single-chain HGF variants.

10 Alternatively or in addition, the replacement of valine at position 495 by another amino acid is expected to block the one-chain to two-chain cleavage. Bulkier amino acids, such as tyrosine, phenylalanine, etc. are preferred for substitution at this position.

Other HGF variants of the present invention are altered at a site within the protease domain of HGF and retain substantially full  
15 receptor binding affinity of the corresponding (preferably human) wild-type HGF. The protease domain follows the cleavage site between amino acid positions 494 and 495 in the wild-type huHGF sequence, and shows a high degree of homology with the catalytic domain of known serine proteases. The conservation does not apply to  
20 the active site of serine proteases. In human plasmin, which is formed from its proenzyme, plasminogen, residues His-42, Asp-85 and Ser-181 form the catalytic site (catalytic triad). This catalytic triad is highly conserved in serine proteases. In the huHGF amino acid sequence asparagine is retained at amino acid position 594,  
25 however, position 534 (corresponding to position 42 of plasmin) is occupied by glutamine instead of histidine, and position 673 (corresponding to position 181 of plasmin) by tyrosine instead of serine. A preferred group of the protease domain alterations herein involves one or both of amino acid positions 673 and 534.  
30 Alternatively, or in addition, the alteration may be at position 692 of the huHGF amino acid sequence. In all instances, the alteration preferably is the substitution of one or more different amino acids for the residues at these positions of the native huHGF amino acid sequence.

35 Tyrosine at amino acid position 673 is preferably replaced by an amino acid which has no bulky aromatic or heterocyclic moieties. Such amino acids include serine, threonine, asparagine, cysteine, glycine,

alanine and valine. In the preferred variants, serine is substituted for tyrosine at this position.

Valine at amino acid position 692 preferably is substituted by a polar amino acid, such as serine, threonine, asparagine or glutamine, preferably serine.

In a preferred group of the HGF amino acid sequence variants herein, both position 673 and position 692 are substituted by one of the foregoing amino acids, preferably serine. Such variants may additionally contain an alteration (preferably substitution) at amino acid position 534. The latter alteration may be the substitution of histidine for glutamine in the wild-type huHGF amino acid sequence.

The single, double or triple mutations within the protease domain may be combined with additional alterations in the wild-type HGF amino acid sequence. Such further alterations may, for example, be at or around the one-chain to two chain cleavage site of the HGF molecule, as hereinabove described, and may result in variants which are substantially in single-chain form.

Additional alterations may be at the C-terminal end and/or in the Kringle domains of the HGF molecule. In addition to the deletion mutants disclosed in the examples, HGF variants with alterations within the Kringle 1 domain are of great interest. As we have found that the receptor binding domain is contained within the finger and the Kringle 1 regions of the HGF molecule, amino acid alterations within these domains are expected to significantly alter the receptor binding properties (and the biological activity) of the variants of the present invention. Alterations at residues that are most exposed to the interior in the Kringle structure (mostly charged residues) are particularly likely to cause profound changes in the receptor binding properties and/or biological activity of the HGF variants.

Alterations within the Kringle 1 domain preferably are within the patch defined by amino acid positions 159, 161, 195 and 197 of the wild-type huHGF amino acid sequence or at corresponding positions in a non-human HGF amino acid sequence. Another preferred site for amino acid alteration is at position 173 of the wild-type huHGF amino acid sequence. The latter position is at the opposite side as compared to the surface defined by amino acid position 159, 161, 195 and 197 and the reasons for its involvement in the binding properties and biological activity of HGF have not yet been fully identified.

Some illustrative huHGF variants within the scope herein are as follows: R494E; R494D; R494A; V495Y; V495F; R494E, V495Y; R494E, V495F; R494D, V495Y; R494D, V495F; R494A, V495Y; R494A, V495F; R494[E]V495; R494[D]V495; R494[A]V495; R494[Y]V495; R494[F]V495;

5 R494E, Q534H; R494E, Y673S; R494E, V692S; R494D, Q534H; R494D, Y673S; R494D, V692S, R494A, Q534H; R494A, V673S; R494A, V692S, R494E, Y673S, V692S; R494D, Y673S, V692S, R494A, Y673S, V692S, R494E, Q534H, Y673S, V692S; R494D, Q534H, Y673S, V692S; R494A, Q534H, Y673S, V692S; E159A; S161A; F162A, L163A, S165A, S166A; F162A; L163A, S165A, S166A; Y167F;

10 Y167A; R168A; Q173A; Q173A, E174A, N175A; N193A; R195A; R197A; N193A, E195A, R197A; K52A; D54A; K52A, D54A; H114A; H114A, E115A, D117A; E115A; D117A; variants with combinations of any of the foregoing alterations;  $\Delta$ K3 and/or  $\Delta$ K4 variants comprising any of the foregoing alterations; corresponding delta5-huHGF variants and non-human animal

15 HGF variants.

### III. Construction of the HGF Variants

Whereas any technique known in the art can be used to perform site-directed mutagenesis, e.g. as disclosed in Sambrook et al.

20 [Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press, New York (1989)], oligonucleotide-directed mutagenesis is the preferred method for preparing the HGF variants of this invention. This method, which is well known in the art [Adelman et al. DNA, 2:183 (1983), Sambrook et al., Supra], is particularly

25 suitable for making substitution variants, it may also be used to conveniently prepare deletion and insertion variants.

As will be appreciated, the site-specific mutagenesis technique typically employs a phage vector that exists in both a single-stranded and double-stranded form. Typical vectors useful in site-directed

30 mutagenesis include vectors such as the M13 phage, for example, as disclosed by Messing et al., Third Cleveland Symposium on Macromolecules and Recombinant DNA, Editor A. Walton, Elsevier, Amsterdam (1981). These phage are readily commercially available and their use is generally well known to those skilled in the art.

35 Alternatively, plasmid vectors that contain a single-stranded phage origin of replication (Veira et al., Meth. Enzymol., 153: 3 (1987)) may be employed to obtain single-stranded DNA.



The oligonucleotides are readily synthesized using techniques well known in the art such as that described by Crea et al. (Proc. Nat'l. Acad. Sci. USA, 75:5765 [1978]).

5 The specific mutagenesis method followed in making the HGF variants of Example 1 was described by Kunkel et al., Methods in Enzymol. 154 367-382 (1987).

Mutants with more than one amino acid substituted may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated  
10 simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If however, the amino acids are located some distance from each other (separated by more than ten amino acids, for example) it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one  
15 of two alternative methods may be employed. In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired  
20 amino acid substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant.

Another method for making mutations in the DNA sequence encoding wild-type HGF or a variant molecule known in the art, involves  
25 cleaving the DNA sequence encoding the starting HGF molecule at the appropriate position by digestion with restriction enzymes, recovering the properly cleaved DNA, synthesizing an oligonucleotide encoding the desired amino acid sequence and flanking regions such as polylinkers with blunt ends (or, instead of polylinkers, digesting the synthetic oligonucleotide with the restriction enzymes also used to cleave the  
30 HGF encoding DNA, thereby creating cohesive termini), and ligating the synthetic DNA into the remainder of the HGF encoding structural gene.

PCR mutagenesis is also suitable for making the HGF variants of the present invention, for example, as described in U.S. Patent No. 4,683,195 issued 28 July 1987 and in Current Protocols in Molecular  
35 Biology, Ausubel et al., eds. Greene Publishing Associates and Wiley-Interscience, Volume 2, Chapter 15, 1991. While the following discussion refers to DNA, it is understood that the technique also find application with RNA. The PCR technique generally refers to the

following procedure. When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation; the sequence of the other primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone. If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to replace the corresponding region in the plasmid that served as PCR template using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second primer or performing a second PCR with different mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or more)-part ligation.

The cDNA encoding the HGF variants of the present invention is inserted into a replicable vector for further cloning or expression.

Suitable vectors are prepared using standard recombinant DNA procedures. Isolated plasmids and DNA fragments are cleaved, tailored, and ligated together in a specific order to generate the desired vectors.

After ligation, the vector with the foreign gene now inserted is transformed into a suitable host cell. The transformed cells are selected by growth on an antibiotic, commonly tetracycline (tet) or ampicillin (amp), to which they are rendered resistant due to the presence of tet and/or amp resistance genes on the vector. If the ligation mixture has been transformed into a eukaryotic host cell,

transformed cells may be selected by the DHFR/MTX system. The transformed cells are grown in culture and the plasmid DNA (plasmid refers to the vector ligated to the foreign gene of interest) is then isolated. This plasmid DNA is then analyzed by restriction mapping and/or DNA sequencing. DNA sequencing is generally performed by either the method of Messing et al., Nucleic Acids Res., 9:309 (1981) or by the method of Maxam et al., Methods of Enzymology, 65:499 (1980).

Prokaryotes are the preferred host cells for the initial cloning steps of this invention. They are particularly useful for rapid production of large amounts of DNA, for production of single-stranded DNA templates used for site-directed mutagenesis, for screening many mutants simultaneously, and for DNA sequencing of the mutants generated. For expressing the HGF variants of the present invention eukaryotic hosts, such as eukaryotic microbes (yeast) and multicellular organisms (mammalian cell cultures) may also be used. Examples of prokaryotes, e.g. E. coli, eukaryotic microorganisms and multicellular cell cultures, and expression vectors, suitable for use in producing the HGF variants of the present invention are, for example, those disclosed in WO 90/02798 (published 22 March 1990).

Cloning and expression methodologies are well known in the art and are, for example, disclosed in the foregoing published PCT patent application (WO 90/02798).

If mammalian cells are used as host cells, transfection generally is carried out by the calcium phosphate precipitation method as described by Graham and Van der Eb, Virology, 52: 546 (1978). However, other methods for introducing DNA into cells such as nuclear injection, electroporation, or protoplast fusion are also suitably used.

If yeast are used as the host, transfection is generally accomplished using polyethylene glycol, as taught by Hinnen, Proc. Natl. Acad. Sci. U.S.A., 75: 1929-1933 (1978).

If prokaryotic cells or cells that contain substantial cell wall constructions are used, the preferred method of transfection is calcium treatment using calcium as described by Cohen et al., Proc. Natl. Acad. Sci. (USA) 69: 2110 (1972), or more recently electroporation.

The HGF variant preferably is recovered from the culture medium as a secreted protein, although it also may be recovered from host cell lysates when directly expressed without a secretory signal. When the variant is expressed in a recombinant cell other than one of human origin, the variant is thus completely free of proteins of human origin. However, it is necessary to purify the variant from recombinant cell proteins in order to obtain preparations that are substantially homogeneous as to protein. As a first step, the culture medium or lysate is centrifuged to remove particulate cell debris.

The variant is then purified from contaminant soluble proteins, for example, by an appropriate combination of conventional chromatography methods, e.g. gel filtration, ion-exchange, hydrophobic interaction, affinity, immunoaffinity chromatography, reverse phase HPLC; precipitation, e.g. ethanol precipitation, ammonium sulfate precipitation, or, preferably, immunoprecipitation with anti-HGF (polyclonal or monoclonal) antibodies covalently linked to Sepharose. Due to its high affinity to heparine, HGF can be conveniently purified on a heparin, such as heparine-Sepharose column. One skilled in the art will appreciate that purification methods suitable for native HGF may require modification to account for changes in the character of HGF or its variants upon expression in recombinant cell culture.

As hereinabove described, huHGF contains four putative glycosylation sites, which are located at positions 294 and 402 of the  $\alpha$ -chain and at positions 566 and 653 of the  $\beta$ -chain. These positions are conserved in the rat HGF amino acid sequence. Glycosylation variants are within the scope herein.

Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side-chain of an asparagine residue. The tripeptide sequences, asparagine-X-serine and asparagine-X-threonine, wherein X is any amino acid except proline, are recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be involved in O-linked glycosylation. O-linked glycosylation sites may, for example, be modified by the addition of, or substitution by, one or more serine or threonine

residue to the amino acid sequence of the HGF molecule. For ease, changes are usually made at the DNA level, essentially using the techniques discussed hereinabove with respect to the amino acid sequence variants.

5        Chemical or enzymatic coupling of glycosydes to the HGF variants of the present invention may also be used to modify or increase the number or profile of carbohydrate substituents. These procedures are advantageous in that they do not require production of the polypeptide that is capable of O-linked (or N-linked) glycosylation. Depending on  
10       the coupling mode used, the sugar(s) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free hydroxyl groups such as those of cysteine, (d) free sulfhydryl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan or (f) the amide group  
15       of glutamine. These methods are described in WO 87/05330 (published 11 September 1987), and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Carbohydrate moieties present on an HGF variant may also be removed chemically or enzymatically. Chemical deglycosylation  
20       requires exposure to trifluoromethanesulfonic acid or an equivalent compound. This treatment results in the cleavage of most or all sugars, except the linking sugar, while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin et al., Arch. Biochem. Biophys. 259, 52 (1987) and by Edge et al., Anal. Biochem. 118, 131 (1981). Carbohydrate moieties can be removed by a  
25       variety of endo- and exoglycosidases as described by Thotakura et al., Meth. Enzymol. 138, 350 (1987). Glycosylation is suppressed by tunicamycin as described by Duskin et al., J. Biol. Chem. 257, 3105 (1982). Tunicamycin blocks the formation of protein-N-glycosydase  
30       linkages.

Glycosylation variants of the amino acid sequence variants herein can also be produced by selecting appropriate host cells. Yeast, for example, introduce glycosylation which varies significantly from that of mammalian systems. Similarly, mammalian cells having a different  
35       species (e.g. hamster, murine, insect, porcine, bovine or ovine) or tissue (e.g. lung, liver, lymphoid, mesenchymal or epidermal) origin than the source of the selectin variant, are routinely screened for the ability to introduce variant glycosylation. Covalent

modifications of an HGF variant molecule are included within the scope herein. Such modifications are traditionally introduced by reacting targeted amino acid residues of the HGF variant with an organic derivatizing agent that is capable of reacting with selected side-chains or terminal residues, or by harnessing mechanisms of post-translational modifications that function in selected recombinant host cells. The resultant covalent derivatives are useful in programs directed at identifying residues important for biological activity, for immunoassays of the HGF variants, or for the preparation of anti-HGF antibodies for immunoaffinity purification of the recombinant glycoprotein. For example, complete inactivation of the biological activity of the protein after reaction with ninhydrin would suggest that at least one arginyl or lysyl residue is critical for its activity, whereafter the individual residues which were modified under the conditions selected are identified by isolation of a peptide fragment containing the modified amino acid residue. Such modifications are within the ordinary skill in the art and are performed without undue experimentation.

Derivatization with bifunctional agents is useful for preparing intramolecular aggregates of the HGF variants as well as for cross-linking the HGF variants to a water insoluble support matrix or surface for use in assays or affinity purification. In addition, a study of interchain cross-links will provide direct information on conformational structure. Commonly used cross-linking agents include 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, homobifunctional imidoesters, and bifunctional maleimides. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithiol]propioimide yield photoactivatable intermediates which are capable of forming cross-links in the presence of light. Alternatively, reactive water insoluble matrices such as cyanogen bromide activated carbohydrates and the systems reactive substrates described in U.S. patent Nos. 3,959,642; 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; 4,055,635; and 4,330,440 are employed for protein immobilization and cross-linking.

Certain post-translational modifications are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminy and aspariginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and aspartyl

residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

5 Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)].

10 Other derivatives comprise the novel HGF variants of this invention covalently bonded to a nonproteinaceous polymer. The nonproteinaceous polymer ordinarily is a hydrophilic synthetic polymer, i.e. a polymer not otherwise found in nature. However, polymers which exist in nature and are produced by recombinant or in  
15 vitro methods are useful, as are polymers which are isolated from nature. Hydrophilic polyvinyl polymers fall within the scope of this invention, e.g. polyvinylalcohol and polyvinylpyrrolidone. Particularly useful are polyvinylalkylene ethers such a polyethylene glycol, polypropylene glycol.

20 The HGF variants may be linked to various nonproteinaceous polymers, such as polyethylene glycol, polypropylene glycol or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The HGF variants may be entrapped in microcapsules prepared, for  
25 example, by coacervation techniques or by interfacial polymerization, in colloidal drug delivery systems (e.g. liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th Edition, Osol, A., Ed. (1980). An  
30 HGF variant sequence can be linked to a immunoglobulin constant domain sequence as hereinbefore defined. The resultant molecules are commonly referred to as HGF variant-immunoglobulin chimeras. Such chimeras can be constructed essentially as described in WO 91/08298 (published 13 June 1991).

35 Ordinarily, the HGF variant is fused C-terminally to the N-terminus of the constant region of an immunoglobulin in place of the variable region(s), however N-terminal fusions of the selectin

variants are also desirable. The transmembrane regions of the HGF variants are preferably inactivated or deleted prior to fusion.

Typically, such fusions retain at least functionally active hinge, CH2 and CH3 domains of the constant region of an immunoglobulin heavy chain. Fusions are also made to the C-terminus of the Fc portion of a constant domain, or immediately N-terminal to the CH1 of the heavy chain or the corresponding region of the light chain. This ordinarily is accomplished by constructing the appropriate DNA sequence and expressing it in recombinant cell culture.

Alternatively, however, the HGF variant-immunoglobulin chimeras of this invention may be synthesized according to known methods.

The precise site at which the fusion is made is not critical; particular sites are well known and may be selected in order to optimize the biological activity, secretion or binding characteristics of the HGF variant.

In some embodiments, the hybrid immunoglobulins are assembled as monomers, or hetero- or homo-multimers, and particularly as dimers of tetramers, essentially as illustrated in WO 91/08298, Supra.

In a preferred embodiment, the C-terminus of a sequence which contains the binding site(s) for an HGF receptor, is fused to the N-terminus of the C-terminal portion of an antibody (in particular the Fc domain), containing the effector functions of an immunoglobulin, e.g. immunoglobulin G<sub>1</sub>. It is possible to fuse the entire heavy chain constant region to the sequence containing the receptor binding site(s). However, more preferably, a sequence beginning in the hinge region just upstream of the papain cleavage site (which defines IgG Fc chemically; residue 216, taking the first residue of heavy chain constant region to be 114 [Kobet et al., Supra], or analogous sites of other immunoglobulins) is used in the fusion. In a particularly preferred embodiment, the amino acid sequence containing the receptor binding site(s) is fused to the hinge region and C<sub>H</sub>2 and C<sub>H</sub>3 or C<sub>H</sub>1, hinge, C<sub>H</sub>2 and C<sub>H</sub>3 domains of an IgG<sub>1</sub>, IgG<sub>2</sub> or IgG<sub>3</sub> heavy chain. The precise site at which the fusion is made is not critical, and the optimal site can be determined by routine experimentation.

HGF variant-immunoglobulin chimeras may, for example, be used in protein A purification, immunohistochemistry, and immunoprecipitation techniques in place of anti-HGF antibodies, and can facilitate screening of inhibitors of HGF-HGF receptor interactions.



Therapeutically, they are expected to confer advantages such as longer half-life as compared to the corresponding HGF variant molecule.

#### IV. Therapeutic Compositions

5       The HGF variants with enhanced receptor binding affinity can be used to block the binding of wild-type HGF to its receptor. This would permit the treatment of pathologic conditions associated with the activation of an HGF receptor, such as malignancies associated with chronic HGF receptor activation.

10       The compounds of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the HGF product is combined in admixture with a pharmaceutically acceptable carrier. Suitable carriers and their formulations are described in Remington's Pharmaceutical Sciences,  
15 16th ed., 1980, Mack Publishing Co., edited by Oslo et al. These compositions will typically contain an effective amount of the HGF variant, for example, from on the order of about 0.5 to about 10 mg/ml, together with a suitable amount of carrier to prepare pharmaceutically acceptable compositions suitable for effective  
20 administration to the patient. The variants may be administered parenterally or by other methods that ensure its delivery to the bloodstream in an effective form.

      Compositions particularly well suited for the clinical administration of the HGF variants used to practice this invention  
25 include sterile aqueous solutions or sterile hydratable powders such as lyophilized protein. Typically, an appropriate amount of a pharmaceutically acceptable salt is also used in the formulation to render the formulation isotonic.

      Dosages and desired drug concentrations of pharmaceutical  
30 compositions of this invention may vary depending on the particular use envisioned. A typical effective dose in rat experiments is about 250 µg/kg administered as an intravenous bolus injection. Interspecies scaling of dosages can be performed in a manner known in the art, e.g. as disclosed in Mordenti et al., Pharmaceut. Res. 8,  
35 1351 (1991) and in the references cited therein.

      The following examples merely illustrate the best mode now contemplated for practicing the invention, but should not be construed to limit the invention.

V. Examples

A series of recombinant huHGF (rhuHGF) variants were produced to determine the structural and functional importance of the cleavage of the prohormone to the  $\alpha/\beta$  dimer and of the Kringle and protease-like domains. Mutations were introduced into the huHGF cDNA in a CMV based expression plasmid and conditioned media from stable populations of human 293 cells expressing each variant were assayed by Western blotting to monitor the size and expression level of the HGF variants.

The concentration of each huHGF derivative was confirmed with two types of sandwich ELISA assays. The differences in expression levels found in ELISA correlated with those observed on Western blots. For most variants, the level of expression was in the range of 1-5 mg/mL. For variants with expression levels below 0.6 mg/mL, the conditioned media was concentrated.

The mitogenic activity on liver cells in primary culture and ability to bind to the HGF receptor was then determined. The extracellular domain of the HGF receptor was fused to the constant region (Fc) of an human IgG and binding was performed in solution.

The construction of the rhuHGF variants, the assay methods and the analysis of the results obtained with the various mutants are described in the following examples.

EXAMPLE 1Recombinant Production of the huHGF Variants

## A. Site-directed mutagenesis

Plasmid DNA isolation, polyacrylamide and agarose gel electrophoresis were performed as disclosed in Sambrook *et al.*, *supra*.

Mammalian expression plasmid pRK 5.1 with a CMV promotor (Genentech, Inc.) was used for mutagenesis of huHGF allowing secretion of the HGF variants in the culture medium and directly assayed for biological activity and binding. This expression vector is a derivative of pRK5, the construction of which is disclosed in EP 307,247 published 15 March 1989. The nucleotide sequence encoding this the pRK 5.1 vector is shown in Figure 5 (SEQ. ID. NO: 1).

The huHGF cDNA used corresponds to the 728 amino acid form as published earlier (Miyazawa *et al.*, 1989, *supra*).

Mutagenesis was performed according to the method of Kunkel using the commercially available dut- ung- strain of *E. coli* [Kunkel *et*

al., Method. Enzymol. 154, 367-382 (1987)]. Synthetic oligonucleotides used for in vitro mutagenesis and sequencing primers were prepared using the Applied Biosystem 380A DNA synthesizer as described [Matteucci et al., J. Am. Chem. Soc. 103, 3185-3191 (1981)].

5 For generation of the desired mutants, oligonucleotides of sequences coding for the desired amino acid substitutions were synthesized and used as primers. The oligonucleotides were annealed to single-stranded pRK51-huHSA that had been prepared by standard procedures [Viera et al., Method. Enzymol. 142, 3 (1987)].

10 A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), was combined with a modified thio-deoxyribonucleosine called dCTP(aS) provided in the kit by the manufacturer, and added to the single stranded pRK 5.1-huHGF to which was annealed the oligonucleotide.

15 Upon addition of DNA polymerase to this mixture, a strand of DNA identical to pRK 5.1-huHGF except for the mutated bases was generated. In addition, this new strand of DNA contained dCTP(aS) instead of dCTP, which served to protect from restriction endonuclease digestion. After the template strand of the double-stranded heteroduplex was  
20 nicked with an appropriate restriction enzyme, the template strand was digested with ExoIII nuclease past the region that contained the mutagenic oligomer. The reaction was then stopped to leave a molecule that was only partly single-stranded. A complete double-stranded DNA homoduplex molecule was then formed by DNA polymerase in the presence  
25 of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase.

The following oligonucleotides were prepared to use as primers to generate pRK 5.1-huHGF variant molecules:

R494E huHGF: TTGGAATCCCATTTACAACCTCGAGTTGTTTCGTTTTGGCACAAGAT

(SEQ. ID. NO: 2)

30 R494D huHGF: GAATCCCATTTACGACGTCCAATTGTTTCG (SEQ. ID. NO: 3)

R494A huHGF: CCCATTTACAACCTGCCAATTGTTTCG (SEQ. ID. NO: 4)

Q534H huHGF: AGAAGGGAAACAGTGTCTGTGCA (SEQ. ID. NO: 5)

Y673S huHGF: AGTGGGCCACCAGAATCCCCCT (SEQ. ID. NO: 6)

V692S huHGF: TCCACGACCAGGAGAAATGACAC (SEQ. ID. NO: 7)

35 AK1 huHGF: GCATTCAACTTCTGAGTTTCTAATGTAGTC (SEQ. ID. NO: 8)

AK2 huHGF: CATAGTATTGTCAGCTTCAACTTCTGAACA (SEQ. ID. NO: 9)

AK3 huHGF: TCCATGTGACATATCTTCAGTTGTTTCCAA (SEQ. ID. NO: 10)

AK4 huHGF: TGTGGTATCACCTTCATCTTGTCCATGTGA (SEQ. ID. NO: 11)

N-303 huHGF: ACCTTGGATGCATTAAGTTGTTTC (SEQ. ID. NO:12)

N-384 huHGF: TTGTCCATGTGATTAATCACAGT (SEQ. ID. NO:13)

$\alpha$ -chain: GTTCGTGTTGGGATCCCATTACCTATCGCAATTG (SEQ. ID. NO:14)

5 The Y673S, V692S huHGF variant was obtained from wild-type huHGF as a template, using both oligonucleotides used for generating the two mutations.

10 The mutant huHGF constructs generated using the protocol above were transformed in *E. coli* host strain MM294tonA using the standard calcium chloride procedure (Sambrook *et al.*, *supra*) for preparation and transformation of competent cells. MM294tonA (which is resistant to T1 phage) was prepared by the insertion and subsequent imprecise excision of a Tn10 transposon into the *tonA* gene. This gene was then inserted, using transposon insertion mutagenesis [Kleckner *et al.*, *J. Mol. Biol.* **116**, 125-159 (1977)], into *E. coli* host MM294 (ATCC 15 31,446).

The DNA extract from individual colonies of bacterial transformants using the standard miniprep procedure of Sambrook *et al.*, *supra*. The plasmids were further purified by passage over a Sephacryl CL6B spin column, and then analyzed by sequencing and by 20 restriction endonuclease digestion and agarose gel electrophoresis.

#### B. Transfection of Human Embryonic Kidney 293 Cells

Plasmids with the correct sequence were used to transfect human fetal kidney 293 cells by the calcium phosphate method. 293 cells were growth to 70% confluence in 6-well plates. 2.5  $\mu$ g of huHGF plasmid 25 DNA variant was dissolved in 150  $\mu$ l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M.CaCl<sub>2</sub>. Added to this (dropwise while vortexing) was 150  $\mu$ l of 50 mM HEPES buffer (pH 7.35), 280 mM NaCl, 1.5 mM NaPO<sub>4</sub>, and the precipitate was allowed to form for ten minutes at 25 °C. The suspended precipitate was then added to the cells in the individual 30 wells in a 6-well plate. The cell monolayers were incubated for 4 hours in the presence of the DNA precipitate, washed once with PBS, and cultured in serum-free medium for 72h. When stable populations were made, the HGF cDNA was subcloned in an episomal CMV driven expression plasmid pCisEBON (G. Cachianes, C. Ho, R. Weber, S. Williams, D. Goeddel, and D. Lueng, in preparation). pCisEBON is a 35 PRK5 derivative; its underlying nucleotide sequence is shown in Figure 6 (SEQ. ID. NO: 15). The populations were directly selected in Neomycin selective medium.

EXAMPLE 2Assay Methods

In view of the pleiotropic activities of HGF, a molecule with a structure unlike any other known growth factor, it is important to understand the molecular interaction of this factor with its receptor. The huHGF variants produced as described in Example 1 were analyzed for their ability to induce DNA synthesis of hepatocytes in primary culture and to compete for binding to a soluble form of the huHGF receptor.

10 A. Protein quantification of wild-type huHGF and huHGF variants.

A specific two-site huHGF sandwich ELISA using two monoclonal antibodies was used to quantify wild-type recombinant huHGF (WT rhuHGF), single chain and protease substitution variants. Microtiter plates (Maxisorb, Nunc) were coated with 10 mg/ml of a monoclonal anti-rhuHGF antibody A 3.1.2 (IgG2a phenotype, affinity:  $3.2 \times 10^{-8}$  mol) in 50 mM Carbonate buffer, pH 9.6, overnight at 4°C. After blocking plates with 0.5 % BSA (Sigma), 0.01 % thimerosal in PBS, pH 7.4, and subsequent washes, duplicate serial dilutions of HGF samples were prepared and in parallel a CHO-expressed rhuHGF (40-0.1 ng/mL) was used as a standard. Fifty microliters of these dilutions were simultaneously incubated with 50 mL of a 1:1500 diluted horseradish peroxidase conjugated monoclonal anti-rhuHGF antibody B 4.3 (IgG1 phenotype, affinity:  $1.3 \times 10^{-8}$  mol) for 2 h at RT. The substrate was prepared by adding 0.04 % o-phenylenediamine-dihydrochloride (Sigma) and 0.012 % (v/v) hydrogen-peroxide (Sigma) to PBS and 100 ml were added to the washed plates for 15 minutes at RT. The reaction was stopped by adding 50 mL of 2.25 M sulfuric acid to each well. The absorbance at 490 nm, with the absorbance at 405 nm subtracted as background, was determined on a microtiter plate reader (Vmax, Molecular Devices, Menlo Park, CA). The data was reduced using a four-parameter curve-fitting program developed at Genentech, Inc.

An HGF polyclonal sandwich ELISA was used to quantify all kringle deletion and C-terminal truncation variants. Briefly, microtiter plates (Nunc) were coated with 5 mg/mL guinea pig polyclonal (anti CHO-expressed rhuHGF) IgG antibody preparation (Genentech, Inc.) as described above. This antibody recognizes rhuHGF as well as HGF truncated forms when compared to visual inspection of Western blots, making it ideal for monitoring HGF variants. Plates were blocked and

duplicate serial dilutions of 293 cell supernatants (1:103-6.106) were added and incubated over night at 4°C. Purified CHO-expressed rhuHGF (100-0.78 ng/mL) was used as a standard and incubated in parallel. Plates were washed and incubated with a 1:500 dilution of the same polyclonal antibody (approx. 400 ng/mL) but in this case horseradish peroxidase conjugated for detection of the variants (see above). Western blotting was performed to determine the size of the expressed HGF variants. For this, SDS-polyacrylamide gel electrophoresis and Western blotting were performed using standard methods with the polyclonal IgG antibody preparation (500 ng/mL). A chemiluminescent detection method (Amersham) and a goat anti-guinea pig IgG-horseradish peroxidase conjugate (1:5000) were used for development of the blot as described by the manufacturer.

B. Soluble HGF receptor binding assay.

Previous studies on HGF binding to hepatocytes have shown that huHGF could bind to its cell surface receptor with high affinity ( $K_d$ -24-32 pM; Higuchi and Nakamura, Biochem. Biophys. Res. Comm. 174, 831-838 (1991)). We preferred to examine HGF binding using a soluble form of the receptor because of the nonspecific binding of HGF to cell surface heparin sulfate proteoglycans [Naldini et al., EMBO J. 10, 2867-2878 (1991)].

Cell supernatants (concentrated on Amicon filters if concentration was below 600 ng/mL) were tested for their ability to block in solution the binding of CHO-expressed  $^{125}I$  rhuHGF (2-5 x 10<sup>3</sup> Ci/mmoles, kindly provided by T. Zioncheck, Genentech, Inc.) to the extracellular domain of the human HGF receptor (huHGFr) fused to the Fc constant region of an human IgG, expressed and secreted from 293 cells.

1.. Construction of huHGFr-IgG chimeras.

A full length cDNA clone encoding the huHGFr was constructed by joining partial cDNAs isolated from cDNA libraries and from PCR amplification. Coding sequences for amino acids 1-270 were isolated from a human placental cDNA library (provided by T. Mason, Genentech) screened with a 50 mer oligonucleotide (5'-ATGAAGGCCCCGCTGTGCTTGACCTGGCATCCTCGTGCTCCTGTTTACC-3') (SEQ. ID. NO: 16). Sequences encoding amino acids 809-1390 were isolated from a human liver library (Stragagen) screened with the oligonucleotide probe

(5'-CACTAGTTAGGATGGGGGACATGTCTGTCTGAGAGGATACTGCACTTGTGGGCATGAA CCGT-3').  
(SEQ. ID. NO: 17)

Conditions for plating libraries, and for hybridization and washing filters were as described [Godowski *et al.*, *Proc. Natl. Acad. Sci. USA* **86**, 8083-8087 (1989)]. PCR was used to isolate a cDNA clone containing residues 271-808 of the HGFr (*c-met*) from A549 cells. Ten  $\mu$ g of total RNA was used for reverse transcription using a primer specific to the HGFr (5'-TAGTACTAGCACTATGATGTCT-3') (SEQ. ID. NO: 18) in a 100  $\mu$ l reaction using Moloney murine leukemia virus reverse transcriptase and buffers supplied by Bethesda Research Laboratories. One-tenth of this reaction mixture was used for PCR amplification. The PCR reaction was performed in a volume of 100  $\mu$ l containing 10  $\mu$ l of the reverse transcriptase reaction, 10 mM KCl, 20 mM Tris-HCl (pH 8.8), 10 mM (NH<sub>4</sub>)SO<sub>4</sub>, 6 mM MgSO<sub>4</sub>, 0.1% Triton X-100, 1 U of Vent DNA polymerase (New England Biolabs) and 50 pmol each of the forward primer (5'-TTTACTTCTTGACGGTCCAAAG-3') (SEQ. ID. NO: 19) and the reverse primer (5'-CAGGGGGAGTTGCAGATTCAGCTGT-3') (SEQ. ID. NO: 20). After thirty cycles of denaturation (95°C, 1 min), annealing (55°C, 45 secs) and extension (72°C, 2 min), the PCR product were recovered from low-melting temperature agarose gels. The full-length HGFr cDNA was subcloned into vector pRK7 (see WO 90/02798, published 22 March 1990) and double-stranded DNA sequencing was performed by the dideoxynucleotide method.

The coding sequence of the extracellular domain of the huHGFr was fused to those of the human IgG1 heavy chain in a two-step process. PCR was used to generate a fragment with a unique *Bst*EII site 3' to the coding sequences of the HGFr amino acid 929. The 5' primer (located in the vector upstream of the HGFr coding sequences) and the 3' primer (5'-AGTTTGTGCGGTGACCTGATCATTCTGATCTGGTTGAACATTAC-3') (SEQ. ID. NO: 21) were used in a 100  $\mu$ l reaction as described above except that the extension time at 72°C was 3 minutes, and 40 ng of the full length HGFr expression vector was used as template. Following amplification, the PCR product was joined to the human IgG- $\gamma$ 1 heavy chain cDNA through a unique *Bst*EII site in that construct [Bennett *et al.*, *J. Biol. Chem.* **266**, 23060-23067 (1991)]. The resulting construct contained the coding sequences of amino acids 1-929 of the huHGFr fused via the *Bst*EII site (adding the coding sequences for amino acids V and T) to the coding sequences of amino acids 216-443 of the human

IgG- $\gamma$ 1 heavy chain. Sequencing of the construct was carried out as described above.

## 2. Binding assay.

The binding assay was performed in breakable microtiter plates (Nunc) coated o/n at 4°C with 1 mg/mL of rabbit-anti-human IgG Fc specific antibody (Jackson ImmunoResearch) and plates were carefully washed with PBS containing 0.05% Tween 20 (Biorad). After blocking with PBS containing 0.1% BSA, in this same buffer, 50pM of 125I-rhuHGF in 25 mL per well were added. To each well 50 mL of serial dilutions (1:25-1:6000) of cell supernatants, purified CHO-expressed rhuHGF (25,000-0.064 pM) or medium were added in duplicates. Subsequently, 25 mL of 50 pM of HGF receptor:IgG fusion protein were added and the plates were incubated with gentle shaking. After 4 hours, when equilibrium was reached, plates were washed and wells were individually counted in a gamma-counter. The amount of nonspecifically bound radioactivity was estimated by incubating HGF receptor:IgG with a 500-fold excess of unlabelled rhuHGF. The dissociation constant (Kd) of each analogue was calculated at the IC50 from fitted inhibition curves essentially as described (DeBlasi et al., 1989 [?]) using the huHGF concentration determined by ELISA.

## C. Biological assay.

The biological activity of WT huHGF and variants was measured by their abilities to induce DNA synthesis of rat hepatocytes in primary culture. Hepatocytes were isolated according to published perfusion techniques with minor modifications [Garrison and Haynes, J. Biol. Chem. 150, 2269-277 (1975)]. Briefly, the livers of female Sprague Dawley rats (160-180g) were perfused through the portal vein with 100 mL of Ca<sup>++</sup> free Hepes buffered saline containing 0.02% Collagenase type IV (Sigma). After 20 minutes the liver was removed, placed in buffer, gently stirred to separate hepatocytes from connective tissue and blood vessels, and filtered through nylon mesh. Cells were then washed by centrifugation, resuspended at  $1 \times 10^5$  cells/mL in Williams Media E (Gibco) containing Penicillin (100 U/ml), Streptomycin (100 mg/mL), L-Glutamine (2mM), trace elements (0.01%), transferrin (10 mg/mL) and Aprotinin (1 mg/mL). Hepatocytes were incubated in 96-well microtiter plates (Falcon) in the presence of duplicate serial dilutions of either purified CHO-expressed rhuHGF (1-0.031 mg/mL), 293 supernatants (1:4-1:256) or medium. After 48 hours incubation at



37°C, 0.5 mCi 3H-TdR (15 Ci/mmmole, Amersham) was added to each well and incubated for an additional 16 hours. Cells were harvested on filter papers, which were washed, dried and counted in a Beckman counter after addition of scintillation liquid. For each huHGF variant, the specific activity (SA) expressed in units/mg was calculated at half-maximal proliferation (defined as 1 unit/mL) using the HGF concentration obtained in ELISA.

D. Induction of tyrosine phosphorylations on A549 cells.

Human lung carcinoma cells (A549) monolayers were cultured in RPMI 1640 medium containing 10% fetal bovine serum and maintained at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. Serum-starved cells were incubated without or with 200 ng/mL rhuHGF for 5 minutes at 37°C and extracted with lysis buffer containing 50 mM Hepes, 150 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 1 mM EGTA, 10 % Glycerol, 1 % Triton X-100 and a cocktail of protease inhibitors. The lysates were immunoprecipitated with anti-Met COOH antibodies and blotted with anti-phosphotyrosine antibodies (see Western blotting above).

EXAMPLE 3

Analysis of Cleavage Site Mutants

The cleavage site of proteases commonly contains a basic residue at position P1 and two hydrophobic amino acid residues in positions P'1 and P'2, which follow the cleaved peptide bond. The proposed cleavage site of huHGF (P1 R494, P'1 V495, P'2 V496) fits this consensus. We chose to try to block cleavage of huHGF by replacing the P1 R494 with either D, E, or A. The major form of WT rhuHGF expressed in these cells is cleaved into two-chain material as judged by the presence of the  $\alpha$ -chain with an apparent molecular mass of 69 kDa (Fig. 2). Each of these mutations appeared to block processing of rhuHGF because under reducing conditions these variants migrated as a single band at 94 kDa, the predicted size of single-chain HGF. These variants totally lacked the ability to induce the proliferation of hepatocytes in primary culture (Fig. 3A). However, when these variants were analyzed for their ability to compete with WT rhuHGF for binding to the HGF receptor:IgG fusion protein, their inhibition curves were roughly similar to that of WT rhuHGF (Fig. 3B). The K<sub>d</sub> determined from these curves showed that WT rhuHGF binds to the fusion protein with high affinity (50-70pM) whereas all single chain variants showed

approximately a 2- to 10-fold higher  $K_d$  (100-500pM) compared to WT rhuHGF. Results from at least three independent assays are summarized in Table I as residual hepatocyte proliferative activity and receptor binding capacity compared to WT rhuHGF.

5 Our binding studies showed that WT rhuHGF bound to the soluble receptor fusion protein with a single class of high affinity binding sites (50-70 pM), similar to those found on hepatocytes by Higushi and Nakamura (1991). However, binding of HGF on cells may slightly be different since the soluble receptor is actually a dimer held together  
10 by the disulfide bridge of the hinge in the Fc portion of the IgG.

Direct comparison of specific activity (SA) versus  $K_d$  ratios of all single chain variants showed they were inactive at the highest concentration tested ( $SA < 3\%$ ) while receptor binding affinities were only decreased by a factor of 2-3.

15 These results argue strongly that cleavage of HGF into the two-chain form is required for mitogenic activity, i.e. that single-chain HGF is a promitogen and that the uncleaved form of HGF binds to the HGF receptor, albeit with a reduced affinity.

The major form of HGF isolated from placenta [Hernandez *et al.*,  
20 (1992) *J. Cell Physiol.*, in press] or expressed in transfected COS cells [Rubin *et al.*, *Proc. Natl. Acad. Sci. USA* 88, 415-419 (1991)] is in single-chain form. When tested in mitogenic assays, this single-chain form of HGF is found to be biologically active. Taken together with our data, this suggests that this single-chain HGF is activated  
25 to the two-chain form during the mitogenic assay.

A second observation is that single-chain variants retain substantial capacity to bind to the HGF receptor, as suggested by our competition binding assays. This raises the interesting possibility that single-chain HGF may be bound to cell-surface HGF receptor in  
30 vivo in an inactive state and can subsequently be cleaved to the active double-chain form by the appropriate protease.

#### EXAMPLE 4

##### The Effects of Protease Domain Mutations

35 To elucidate the functional importance of the protease domain of HGF, several single, double and triple mutations were made in order to reconstitute a potential serine-protease active site. The construction of these variants is described in Example 1.

We replaced HGF residues Q534 with H, Y673 with S, or V692 with S as either single, double or triple mutations. The analysis of their effects on mitogenic activity and receptor binding showed that the single mutation Q534H did not significantly alter either SA ( $5.2 \times 10^4$  Units/mg) or Kd (60 pM) when compared to wt rhuHGF (respectively  $3.3 \times 10^4$  Units/mg and 70 pM) whereas Y673S and V692S exhibited SA reduced approximately 5- and 10-fold, respectively. In fact, these two variants never reached the maximum plateau seen with WT rhuHGF (approximately 50 % of wt rhuHGF plateau). Interestingly, these variants showed a Kd similar to WT rhuHGF. All other double and triple variants also retained the ability to bind the HGF receptor but they clearly showed a reduced SA (Table I). The residual SA of the double variants Q534H,Y673S and Y673S,V692S and of the triple variant Q534H,Y673S,V692S were less than 3 % compared to WT rhuHGF. However, the Kd of these variants was not significantly different from WT rhuHGF (Table I). These variants indicate that mutations within the  $\beta$ -chain of HGF block mitogenic activity but they are still able to bind to the HGF receptor. Thus, it appears that these mutants are defective in an activity subsequent to receptor binding.

These results show that although the  $\beta$ -chain is not required for receptor binding, certain residues (e.g. Y673 and V692) are critical for the structure and/or activity of HGF. Substitution of the nonpolar residue V692 with the polar residue S might have caused a structural transition if new hydrogen bonds to the active site residue D594, as found in serine-proteases, have been introduced. Substitution of Y673 with the smaller residue S might also introduce some local structural modifications. On the other hand, replacement of the polar residue Q534 by another polar residue H of similar size would not likely cause a drastic difference in the HGF conformation as this residue should be exposed; indeed the Q534H variant was similar to rhuHGF (Table I).

#### EXAMPLE 5

##### The Effect of C-terminal and Kringle Deletions

In order to ascertain whether the  $\alpha$ -chain is required for HGF binding or activity, C-terminal truncations were made as described in Example 1, resulting in variants containing either the  $\alpha$ -chain alone,

or variants truncated after the third (N-384) or second (N-303) Kringles.

A number of C-terminal truncations of HGF were made by deleting either the  $\beta$ -chain or the  $\beta$ -chain in addition to a progressive number of kringles as depicted in Fig. 1. One variant (N-207) corresponding to the N-terminal domain with the first Kringle did not express the protein to levels detectable either by Western blotting or ELISA using a polyclonal antibody preparation and thus was not investigated further. Expression of the variants containing the first two Kringles (N-303), three Kringles (N-384) or the complete  $\alpha$ -chain of HGF was as low as 250-600 ng/mL. A summary of the residual SA and Kd compared to WT rhuHGF of these variants is presented in Table I. At the concentration tested no activity above background levels was observed indicating that these variants lost their biological activity. However, binding competition showed that variants N-303, N-384 or the  $\alpha$ -chain still retained substantial binding capacity (up to 23 % compared to WT rhuHGF binding). Thus, the N-terminal 272 residues of HGF (the mature form of variant N-303) are sufficient for high affinity binding to the HGF receptor. Results from deleting each kringle domain are shown in Table 1. Deletion of the first Kringle (variant AK1) of HGF affected biological activity most, showing at least a 100-fold reduction (SA < 0.2% of wt rhuHGF). Similarly, binding of this variant was also affected as it failed to compete for binding with wt rhuHGF up to 2 mg/mL. Deletion of all other Kringles (variants AK2, AK3 or AK4) also induces severely reduced mitogenic activity (Table I). However, the Kds of these deletion variants remained close to that observed with wt rhuHGF.

These data show that Kringles K3 and K4 are not required for receptor binding. Our data support the previous observations by Miyazawa *et al.*, 1991 *supra* and Chan *et al.*, 1991 *supra*, in the sense that variant N-303, which in amino acid sequence is very similar to HGF/NK2, retains the ability to compete efficiently for binding to the HGF receptor (Kd=280 pM). Furthermore, the observations that N-303 is sufficient to bind to the receptor and that the second Kringle is not required for binding the HGF receptor (in the context of the remainder of the molecule) suggest that the receptor binding domain is contained within the finger and first Kringle of huHGF. Unfortunately, we have not been able to detect expression of this

variant using our polyclonal antisera suggesting that variant N-207 (deletion after the first kringle) was not expressed in 293 cells.

#### EXAMPLE 6

##### 5        Induction of Tyrosine-Phosphorylation of the huHGF Receptor

We determined if variants R494E or Y673S,V692S, which bind the HGF receptor in vitro but are defective for mitogenic activity, could stimulate tyrosine-phosphorylation of the HGF receptor in A549 cells. Serum starved cells were treated with purified WT rhuHGF or variants  
10       and immunoprecipitates of the HGF receptor were blotted and probed with phosphotyrosine antibodies. Stimulation with wt rhuHGF led to the phosphorylation on tyrosine of the 145 kDa  $\beta$ -subunit of the HGF receptor (Fig. 4). Both variants exhibited a reduced ability to induce phosphorylation of the HGF receptor.

15       Stimulation of tyrosine phosphorylation on the HGF receptor  $\beta$ -subunit by HGF was previously reported [Bottaro et al., Science 251, 802-804 (1991), Naldini et al., 1991 supra]. The present data show that variants R494E and Y673S,V692S can bind the soluble HGF receptor: IgG protein in vitro but are not efficient in stimulating tyrosine-  
20       phosphorylation in A549 cells. One interpretation of this result is that these variants are capable of binding the HGF receptor on A549 cells, but are defective in a function required to induce efficient phosphorylation, e.g. receptor dimerization. It has been shown for  
25       other receptor proteins with an intrinsic tyrosine kinase such as the epithelial and platelet-derived growth factor that receptor-receptor interactions or dimerization is required for activation of kinase function [see for review Ulrich and Schlessinger, Cell 61 203-212 (1990)]. Alternatively, these variants may not be able to bind the cell-surface associated HGF receptor.

30       The unique structure of HGF suggests that there may be multiple events that regulate the biological activity of this molecule. An early stage of regulation may be the cleavage step to generate the biologically active two-chain form. Interestingly, cleavage may not simply regulate receptor binding but rather control a subsequent event  
35       required for activating the HGF receptor. Our data also suggest that the  $\beta$ -chain, while not absolutely required for receptor binding contributes to a receptor activation step. These variants may be useful in dissecting the signalling events at the HGF receptor.

EXAMPLE 7Hairpin Domain and Kringle 1 Domain Variants

The huHGF variants listed in Tables 2 and 3 were generated, and their specific activities (SA) and Kd ratios were determined  
5 essentially as described in the foregoing examples.

-----  
Although the foregoing refers to particular preferred  
embodiments, it will be understood that the present invention is not  
so limited. It will occur to those ordinarily skilled in the art that  
10 various modifications may be made to the disclosed embodiments without  
diverting from the overall concept of the invention. All such  
modifications are intended to be within the scope of the present  
invention.

15

Table 1

Variants (var)		SA var/SA wt	Kdwt/Kdvar
		+/- S.D.	+/- S.D.
<b>Single-chain</b>			
5	R494A	<0.03	0.32 +/- 0.18
	R494D	<0.03	0.51 +/- 0.21
	R494E	<0.02	0.31 +/- 0.13
<b>Protease</b>			
10	Q534H	1.19 +/- 0.44	1.48 +/- 0.85
	Y673S	0.27 +/- 0.07*	1.35 +/- 0.72
	V692S	0.08 +/- 0.04	1.02 +/- 0.13
	Q534H, Y673S	<0.03	2.24 +/- 1.11
	Y673S, V692S	<0.02	1.76 +/- 0.63
	Q534H, Y673S, V692S	<0.02	1.91 +/- 1.28
<b>C-terminal truncation</b>			
15	N-303	<0.05	0.23 +/- 0.03
	N-384	<0.05	0.25 +/- 0.02
	$\alpha$ -chain	<0.04	0.25 +/- 0.03
<b>Kringle deletion</b>			
20	$\Delta$ K1	<0.002	<0.03
	$\Delta$ K2	<0.05	0.41 +/- 0.18
	$\Delta$ K3	<0.03	0.56 +/- 0.36
	$\Delta$ K4	<0.07	0.86 +/- 0.46

25 \* means that the mitogenic activity of the variant did not reach the same absolute level as wild-type huHGF.

Table 2

HGF variant	n	SA mut/wt +/-SD	n	Kdwt/mut
wt rhuHGF	3	1	3	1
K137A	3	1.12 +/- 0.10	3	0.98 +/- 0.04
K144A, K148A	3	0.93 +/- 0.16	3	1.03 +/- 0.08
E159A	3	< 0.02	3	< 0.03
S161A	3	0.15 +/- 0.03*	3	0.06 +/- 0.04
F162A, L163A, S165A, S166A	3	< 0.02	3	0.05 +/- 0.02
F162A	3	0.04 +/- 0.01*	3	0.05 +/- 0.01
L163A, S165A, S166A	3	0.14 +/- 0.08	3	1.10 +/- 0.04
Y167A	3	1.22 +/- 0.22*	3	0.92 +/- 0.06
Y167F	3	0.38 +/- 0.03*	3	1.02 +/- 0.02
delta5-Y167A	3	< 0.02	3	< 0.02
delta5-Y167F	3	0.11 +/- 0.02	3	1.01 +/- 0.13
R168A	3	0.83 +/- 0.07	3	0.98 +/- 0.04
Q173A, E174A, N175A	3	0.33 +/- 0.07*	3	0.21 +/- 0.03
Q173A	3	0.13 +/- 0.03*	3	0.15 +/- 0.05
E174A	3	0.84 +/- 0.11	3	0.99 +/- 0.02
R181A, E183A, E184A	3	0.92 +/- 0.08	3	0.95 +/- 0.04
N193A, E195A, R197A	3	< 0.02	3	< 0.04
N193A	3	0.45 +/- 0.12	3	0.62 +/- 0.20
R195A	3	0.10 +/- 0.06	3	0.17 +/- 0.05
R197A	3	< 0.01	3	< 0.03
Y198A	3	0.88 +/- 0.06	2	0.77

\* means that the mitogenic activity of the variant did not reach the same absolute level as wild-type huHGF.



Table 3  
Variants with alterations near or within the Hairpin Domain

HGF variant	n	SA +/- mut/wt	n	Kd wt/mut
wt rhuHGF	3	1	3	1
delta-hairpin	3	< 0.01	3	< 0.02
K34A, R35A, R36A	3	0.71 +/- 0.33	3	0.95 +/- 0.03
K52A, D54A	3	0.32 +/- 0.03*	3	0.95 +/- 0.03
K52A	3	0.19 +/- 0.03	3	0.89 +/- 0.05
D54A	3	0.13 +/- 0.01	3	0.79 +/- 0.10
K58A, K60A, K62A, K63A, N65A	3	0.96 +/- 0.12	3	0.99 +/- 0.07
N72A, R76A, N77A, K78A	3	0.04 +/- 0.07	3	0.83 +/- 0.11
K109A, K110A, E111A	3	0.98 +/- 0.04	3	0.78 +/- 0.02
H114A, E115A, D117A	3	< 0.02	3	< 0.04
H114A	3	0.16 +/- 0.04*	2	0.59
E115A	3	0.20 +/- 0.02*	2	0.47
D117A	3	0.02*	2	0.14
R126A, N127A	3	0.33 +/- 0.14	3	0.87 +/- 0.12

\* means that the mitogenic activity of the variant did not reach the same absolute level as wild-type huHGF.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Genentech, Inc., Godowski, Paul J., Lokker, Natalie A., Mark, Melanie R.
- (ii) TITLE OF INVENTION: HEPATOCYTE GROWTH FACTOR VARIANTS
- 10 (iii) NUMBER OF SEQUENCES: 21
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Genentech, Inc.
- (B) STREET: 460 Point San Bruno Blvd
- 15 (C) CITY: South San Francisco
- (D) STATE: California
- (E) COUNTRY: USA
- (F) ZIP: 94080
- 20 (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: patin (Genentech)
- 25 (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:
- 30 (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: 07/884811
- (B) FILING DATE: 18-MAY-92
- 35 (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: 07/885971
- (B) FILING DATE: 18-MAY-92
- (viii) ATTORNEY/AGENT INFORMATION:
- 40 (A) NAME: Dreger, Ginger R.
- (B) REGISTRATION NUMBER: 33,055
- (C) REFERENCE/DOCKET NUMBER: 755,779P1
- (ix) TELECOMMUNICATION INFORMATION:
- 45 (A) TELEPHONE: 415/225-3216
- (B) TELEFAX: 415/952-9881
- (C) TELEX: 910/371-7168
- (2) INFORMATION FOR SEQ ID NO:1:
- 50 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 4732 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- 55 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5 TTCGAGCTCG CCCGACATTG ATTATTGACT AGTTATTAAT AGTAATCAAT 50  
TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTTCCGC GTTACATAAC 100  
10 TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG 150  
ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA 200  
15 TTGACGTCAA TGGGTGGAGT ATTTACGGTA AACTGCCCAC TTGGCAGTAC 250  
ATCAAGTGTA TCATATGCCA AGTACGCCCC CTATTGACGT CAATGACGGT 300  
20 AAATGGCCCG CCTGGCATTG TGCCAGTAC ATGACCTTAT GGGACTTTCC 350  
25 TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC ATGGTGATGC 400  
GGTTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA 450  
30 TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACCA 500  
AAATCAACGG GACTTTCCAA AATGTCGTAA CAACTCCGCC CCATTGACGC 550  
35 AAATGGGCGG TAGGCGTGTA CGGTGGGAGG TCTATATAAG CAGAGCTCGT 600  
40 TTAGTGAACC GTCAGATCGC CTGGAGACGC CATCCACGCT GTTTTGACCT 650  
CCATAGAAGA CACCGGGACC GATCCAGCCT CCGCGGCCCG GAACGGTGCA 700  
45 TTGGAACGCG GATTCCCCGT GCCAAGAGTG ACGTAAGTAC CGCCTATAGA 750  
GTCTATAGGC CCACCCCTT GGCTTCGTTA GAACGCGGCT ACAATTAATA 800  
50 CATAACCTTA TGTATCATAC ACATACGATT TAGGTGACAC TATAGAATAA 850  
55 CATCCACTTT GCCTTTCTCT CCACAGGTGT CCACTCCCAG GTCCAACCTGC 900

ACCTCGGTTTC TATCGATTGA ATTCCTCCGGG GATCCTCTAG AGTCGACCTG 950

5 CAGAAGCTTG CCTCGAGGCA AGCTTGGCCG CCATGGCCCA ACTTGTTTAT 1000

TGCAGCTTAT AATGGTTACA AATAAAGCAA TAGCATCACA AATTTACAA 1050

10 AATAAGCATT TTTTCACTG CATTCTAGTT GTGGTTTGT CAAACTCATC 1100

AATGTATCTT ATCATGTCTG GATCGATCGG GAATTAATTC GCGCGAGCAC 1150

15 CATGGCCTGA AATAACCTCT GAAAGAGGAA CTTGGTTAGG TACCTTCTGA 1200

GGCGGAAAGA ACCAGCTGTG GAATGTGTGT CAGTTAGGGT GTGGAAAGTC 1250

20 CCCAGGCTCC CCAGCAGGCA GAAGTATGCA AAGCATGCAT CTCAATTAGT 1300

CAGCAACCAG GTGTGGAAAG TCCCCAGGCT CCCCAGCAGG CAGAAGTATG 1350

CAAAGCATGC ATCTCAATTA GTCAGCAACC ATAGTCCCGC CCCTAACTCC 1400

30 GCCCATCCCG CCCCTAACTC CGCCCACTTC CGCCCATCTT CCGCCCCATG 1450

GCTGACTAAT TTTTTTTATT TATGCAGAGG CCGAGGCCGC CTCGGCCTCT 1500

35 GAGCTATTCC AGAAGTAGTG AGGAGGCTTT TTTGGAGGCC TAGGCTTTTG 1550

CAAAAAGCTG TTAACAGCTT GGCACCTGGC GTCGTTTTAC AACGTCGTGA 1600

CTGGGAAAAC CCTGGCGTTA CCCAACTTAA TCGCCTTGCA GCACATCCCC 1650

45 CCTTCGQCAG CTGGCGTAAT AGCGAAGAGG CCCGCACCGA TCGCCCTTCC 1700

CAACAGTTGC GTAGCCTGAA TGGCGAATGG CGCCTGATGC GGTATTTTCT 1750

50 CCTTACGCAT CTGTGCGGTA TTTCACACCG CATACGTCAA AGCAACCATA 1800

55 GTACGCGCCC TGTAGCGGCG CATTAAAGCGC GCGGGGTGT GTGGTIACGC 1850

GCAGCGTGAC CGCTACACTT GCCAGCGCCC TAGCGCCCGC TCCTTTCGCT 1900

5 TTCTTCCCTT CCTTCTCGC CACGTTCCGC GGCTTTCGCC GTCAAGCTCT 1950

AAATCGGGGG CTCCCTTTAG GGTCCGATT TAGTGCTTTA CGGCACCTCG 2000

10 ACCCCAAAAA ACTTGATTTG GGTGATGGTT CACGTAGTGG GCCATCGCCC 2050

TGATAGACGG TTTTTCGCCC TTTGACGTTG GAGTCCACGT TCTTTAATAG 2100

15 TGGACTCTTG TTCCAACTG GAACAACACT CAACCCTATC TCGGGCTATT 2150

CTTTTGATTT ATAAGGGATT TTGCCGATTT CGGCCTATTG GTTAAAAAAT 2200

20 GAGCTGATTT AACAAAAATT TAACGCGAAT TTTAACAAAA TATTAACGTT 2250

25 TACAATTTTA TGGTGCACTC TCAGTACAAT CTGCTCTGAT GCCGCATAGT 2300

TAAGCCAACT CCGCTATCGC TACGTGACTG GGTGATGGCT GCGCCCCGAC 2350

30 ACCCGCCAAC ACCCGCTGAC GCGCCCTGAC GGGCTTGTCT GCTCCCGGCA 2400

TCCGCTTACA GACAAGCTGT GACCGTCTCC GGGAGCTGCA TGTGTCAGAG 2450

35 GTTTTCACCG TCATCACCBA AACGCGCGAG GCAGTATTCT TGAAGACGAA 2500

40 AGGGCCTCGT GATACGCCTA TTTTATAGG TTAATGTCAT GATAATAATG 2550

GTTTCTTAGA CGTCAGGTGG CACTTTTCGG GGAAATGTGC GCGGAACCCC 2600

45 TATTTGTTTA TTTTCTAAA TACATTCAAA TATGTATCCG CTCATGAGAC 2650

AATAACCCTG ATAAATGCTT CAATAATATT GAAAAAGGAA GAGTATGAGT 2700

50 ATTCAACATT TCCGTGTCGC CCTTATCCC TTTTTCGCGG CATTTTGCCT 2750

55 TCCTGTTTTT GCTCACCCAG AAACGCTGGT GAAAGTAAAA GATGCTGAAG 2800

ATCAGTTGGG TGCACGAGTG GGTACATCG AACTGGATCT CAACAGCGGT 2850

5 AAGATCCTTG AGAGTTTTCG CCCCGAAGAA CGTTTTCCAA TGATGAGCAC 2900

TTTTAAAGTT CTGCTATGTG GCGCGGTATT ATCCCGTGAT GACGCCGGGC 2950

10 AAGAGCAACT CGGTCGCCGC ATACACTATT CTCAGAATGA CTTGGTTGAG 3000

TACTCACCAG TCACAGAAAA GCATCTTACG GATGGCATGA CAGTAAGAGA 3050

15 ATTATGCAGT GCTGCCATAA CCATGAGTGA TAACACTGCG GCCAACTTAC 3100

TTCTGACAAC GATCGGAGGA CCGAAGGAGC TAACCGCTTT TTTGCACAAC 3150

20 ATGGGGGATC ATGTAACCTG CCTTGATCGT TGGGAACCGG AGCTGAATGA 3200

25 AGCCATACCA AACGACGAGC GTGACACCAC GATGCCAGCA GCAATGGCAA 3250

CAACGTTGCG CAAACTATTA ACTGGCGAAC TACTTACTCT AGCTTCCCGG 3300

30 CAACAATTAA TAGACTGGAT GGAGGCGGAT AAAGTTGCAG GACCACTTCT 3350

GCGCTCGGCC CTTCCGGCTG GCTGGTTTAT TGCTGATAAA TCTGGAGCCG 3400

35 GTGAGCGTGG GTCTCGCGGT ATCATTCAG CACTGGGGCC AGATGGTAAG 3450

40 CCTCCCCTA TCGTAGTTAT CTACACGACG GGGAGTCAGG CAACTATGGA 3500

TGAACGAAAT AGACAGATCG CTGAGATAGG TGCCTCACTG ATTAAGCATT 3550

45 GGTAAGTGC AGACCAAGTT TACTCATATA TACTTTAGAT TGATTTAAAA 3600

CITCATTTTT AATTTAAAAG GATCTAGGTG AAGATCCTTT TTGATAATCT 3650

50 CATGACCAAA ATCCCTTAAC GTGAGTTTTT GTTCCACTGA GCGTCAGACC 3700

55 CCGTAGAAAA GATCAAAGGA TCTTCTTGAG ATCCTTTTTT TCTGCGCGTA 3750

ATCTGCTGCT TGCAAACAAA AAAACCACCG CTACCAGCGG TGGTTTGT TT 3800

5 GCCGGATCAA GAGCTACCAA CTCTTTTTCC GAAGGTA ACT GGCTTCAGCA 3850

GAGCGCAGAT ACCAAATACT GTCCTTCTAG TGTAGCCGTA GTTAGGCCAC 3900

10 CACTTCAAGA ACTCTGTAGC ACCGCCTACA TACCTCGCTC TGCTAATCCT 3950

GTTACCA GTG GCTGCTGCCA GTGGCGATAA GTCGTGTCTT ACCGGGTTGG 4000

15 ACTCAAGACG ATAGTTACCG GATAAGGCGC AGCGGTCGGG CTGAACGGGG 4050

GGTTCGTGCA CACAGCCCAG CTTGGAGCGA ACGACCTACA CCGAACTGAG 4100

20 ATACCTACAG CGTGAGCATT GAGAAAGCGC CACGCTTCCC GAAGGGAGAA 4150

AGGCGGACAG GTATCCGGTA AGCGGCAGGG TCGGAACAGG AGAGCGCACG 4200

AGGGAGCTTC CAGGGGGAAA CGCCTGGTAT CTTTATAGTC CTGTCGGGTT 4250

30 TCGCCACCTC TGA CTGAGC GTCGATTTTT GTGATGCTCG TCAGGGGGGC 4300

GGAGCCTATG GAAAAACGCC AGCAACGCGG CCTTTTTACG GTTCCTGGCC 4350

35 TTTTGCTGGC CTTTGCTCA CATGTTCTTT CCTGCGTTAT CCCCTGATT 4400

40 TGTGGATAAC CGTATTACCG CTTTGAGTG AGCTGATACC GCTCGCCGCA 4450

GCCGAACGAC CGAGCGCAGC GAGTCAGTGA GCGAGGAAGC GGAAGAGCGC 4500

45 CCAATACGCA AACCGCCTCT CCCCGCGCGT TGGCCGATT 4550

CTGGCACGAC AGGTTTCCCG ACTGGAAAGC GGGCAGTGAG CGCAACGCAA 4600

50 TTAATGTGAG TTACCTCACT CATTAGGCAC CCCAGGCTTT AACTTTATG 4650

55 CTCCGGCTC GTATGTTGTG TGGAATTGTG AGCGGATAAC AATTTACAC 4700

AGGAAACAGC TATGACCATG ATTACGAATT AA 4732

5 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 bases  
(B) TYPE: nucleic acid  
10 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15

TTGGAATCCC ATTTACAACC TCGAGTTGTT TCGTTTGGC ACAAGAT 47

20 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 bases  
(B) TYPE: nucleic acid  
25 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

30

GAATCCCATT TACGACGTCC AATGTTTCG 30

35 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 bases  
(B) TYPE: nucleic acid  
40 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

45

CCCATTTACA ACTGCCAATT GTTTCG 26

50 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 bases  
(B) TYPE: nucleic acid  
55 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AGAAGGGAAA CAGTGTCGTG CA 22

5

(2) INFORMATION FOR SEQ ID NO:6:

10 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGTGGGCCAC CAGAATCCCC CT 22

20

(2) INFORMATION FOR SEQ ID NO:7:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TCCACGACCA GGAGAAATGA CAC 23

35

(2) INFORMATION FOR SEQ ID NO:8:

40 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCAATCAACT TCTGAGTTTC TAATGTAGTC 30

50

(2) INFORMATION FOR SEQ ID NO:9:

55 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 bases

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CATAGTATTG TCAGCTTCAA CTTCCTGAACA 30

10

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 bases
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TCCATGTGAC ATATCTTCAG TTGTTTCCAA 30

25

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 30 bases
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TGTGGTATCA CCTTCATCTT GTCCATGTGA 30

40

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 bases
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ACCTTGGATG CATTAAGTTG TTTC 24

55

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 23 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

10

TTGTCCATGT GATTAATCAC AGT 23

15

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 35 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

25

GTTTCGTGTTG GGATCCCATT TACCTATCGC AATTG 35

30

## (2) INFORMATION FOR SEQ ID NO:15:

## (i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 10596 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

40

TTCGAGCTCG CCCGACATTG ATTATGACT AGTTATTAAT AGTAATCAAT 50

45

TACGGGGTCA TTAGTTCATA GCCCATATAT GGAGTCCGC GTTACATAAC 100

TTACGGTAAA TGGCCCGCCT GGCTGACCGC CCAACGACCC CCGCCCATTG 150

50

ACGTCAATAA TGACGTATGT TCCCATAGTA ACGCCAATAG GGACTTTCCA 200

55

TTGACGTCAA TGGGTGGAGT ATTTACGGTA AACTGCCCAC TTGGCAGTAC 250

ATCAAGTGTA TCATATGCCA AGTACGCCCC CTATTGACGT CAATGACGGT 300

5 AAATGGCCCG CCTGGCATTG TGGCCAGTAC ATGACCTTAT GGGACTTTCC 350

TACTTGGCAG TACATCTACG TATTAGTCAT CGCTATTACC ATGGTGATGC 400

10 GGTTTTGGCA GTACATCAAT GGGCGTGGAT AGCGGTTTGA CTCACGGGGA 450

TTTCCAAGTC TCCACCCCAT TGACGTCAAT GGGAGTTTGT TTTGGCACCA 500

15 AAATCAACGG GACTTTCCAA AATGTCGTAA CAACTCCGCC CCATTGACGC 550

AAATGGGCGG TAGGCGTGTA CGGTGGGAGG TCTATATAAG CAGAGCTCGT 600

20 TTAGTGAACC GTCAGATCGC CTGGAGACGC CATCCACGCT GTTTTGACCT 650

25 CCATAGAAGA CACCGGGACC GATCCAGCCT CCGCGGCCGG GAACGGTGCA 700

TTGGAAQCGG GATTCCCCGT GCCAAGAGTG ACGTAAGTAC CGCCTATAGA 750

30 GTCTATAGGC CCACCCCTT GGCCTCGTTA GAACGCGGCT ACAATTAATA 800

CATAACCTTA TGTATCATAC ACATACGATT TAGGTGACAC TATAGAATAA 850

35 CATCCAETTT GCCTTTCTCT CCACAGGTGT CCACTCCAG GTCCAAGTGC 900

40 ACCTCGGTTT TATCGATTCT CGAGAATTAA TTCAAGCTTG CGGCCGCAGC 950

TTGGCCGCCA TGGCCCAACT TGTTTATTGC AGCTTATAAT GGTACAAAT 1000

45 AAAGCAATAG CATCACAAAT TTCACAAATA AAGCATTTTT TTCCTGCAT 1050

TCTAGTTGTG GTTTGTCCAA ACTCATCAAT GTATCTTATC ATGTCTGGAT 1100

50 CGATCGGGAA TTAATTCCGC GCAGCACCAT GGCCTGAAAT AACCTCTGAA 1150

55 AGAGGAACTT GGTTAGGTAC CTTCTGAGGC GGAAAGAACC AGCTGTGGAA 1200

TGTGTGTCAG TTAGGGTGTG GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA 1250

5 GTATGCAAAG CATGCATCTC AATTAGTCAG CAACCAGGTG TGGAAAGTCC 1300

CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AGCATGCATC TCAATTAGTC 1350

10 AGCAACCATA GTCCCGCCCC TAACTCCGCC CATCCCGCCC CTAATCCGC 1400

CCAGTTCCGC CCATTCTCCG CCCCATGGCT GACTAATTTT TTTTATTTAT 1450

15 GCAGAGGCCG AGGCCGCCCTC GGCCTCTGAG CTATTCCAGA AGTAGTGAGG 1500

20 AGGCTTTTTT GGAGGCCTAG GCTTTTGCAA AAAGCTGTTT ACGTGATGAA 1550

TTCTCATGTT TGACAGCTTA TCATCGATAG ATCCTCACAG GCCGCACCCA 1600

25 GCTTTTCTTC CGTTGCCCCA GTAGCATCTC TGTCTGGTGA CTTGAAGAG 1650

GAAGAGGAGG GGTCCCGAGA ATCCCATCC CTACCGTCCA GCAAAAAGGG 1700

30 GGACGAGGAA TTTGAGGCCT GGCTTGAGGC TCAGGACGCA AATCTTGAGG 1750

ATGTTTACCG GGAGTTTTC GGGCTGCGAG TAATTGGTGA TGAGGACGAG 1800

35 GATGGTTCCG AGGATGGGGA ATTTTCAGAC CTGGATCTGT CTGACAGCGA 1850

40 CCATGAAGGG GATGAGGGTG GGGGGGCTGT TGGAGGGGGC AGGAGTCTGC 1900

ACTCCCTGTA TTTACTGAGC GTCGTCTAAT AAAGATGTCT ATTGATCTCT 1950

45 TTTAGTGTGA ATCATGTCTG ACGAGGGGCC AGGTACAGGA CCTGGAAATG 2000

GCCTAGGAGA GAAGGGAGAC ACATCTGGAC CAGAAGGCTC CGGCGGCAGT 2050

50 GGACCTCAAA GAAGAGGGGG TGATAACCAT GGACGAGGAC GGGGAAGAGG 2100

55 ACGAGGACGA GGAGGCGGAA GACCAGGAGC CCCGGGCGGC TCAGGATCAG 2150

GGCCAAGACA TAGAGATGGT GTCCGGAGAC CCCAAAAACG TCCAAGTTGC 2200

5 ATTGGCTGCA AAGGGACCCA CGGTGGAACA GGAGCAGGAG CAGGAGCGGG 2250

AGGGGCAGGA GCAGGAGGGG CAGGAGCAGG AGGAGGGGCA GGAGCAGGAG 2300

10 GAGGGGCAGG AGGGGCAGGA GGGGCAGGAG GGGCAGGAGC AGGAGGAGGG 2350

GCAGGAGCAG GAGGAGGGGC AGGAGGGGCA GGAGGGGCAG GAGCAGGAGG 2400

15 AGGGGCAGGA GCAGGAGGAG GGGCAGGAGG GGCAGGAGCA GGAGGAGGGG 2450

CAGGAGGGGC AGGAGGGGCA GGAGCAGGAG GAGGGGCAGG AGCAGGAGGA 2500

20 GGGGCAGGAG GGGCAGGAGC AGGAGGAGGG GCAGGAGGGG CAGGAGGGGC 2550

AGGAGCAGGA GCAGGGGCAG GAGCAGGAGG GGCAGGAGGG GCAGGAGGGG 2600

25 CAGGAGCAGG AGGGGCAGGA GCAGGAGGAG GGGCAGGAGG GGCAGGAGGG 2650

30 GCAGGAGCAG GAGGGGCAGG AGCAGGAGGG GCAGGAGCAG GAGGGGCAGG 2700

AGCAGGAGGG GCAGGAGGGG CAGGAGCAGG AGGGGCAGGA GGGGCAGGAG 2750

35 CAGGAGGGGC AGGAGGGGCA GGAGCAGGAG GAGGGGCAGG AGGGGCAGGA 2800

40 GCAGGAGGAG GGGCAGGAGG GGCAGGAGCA GGAGGGGCAG GAGGGGCAGG 2850

AGCAGGAGGG GCAGGAGGGG CAGGAGCAGG AGGGGCAGGA GGGGCAGGAG 2900

45 CAGGAGGAGG GGCAGGAGCA GGAGGGGCAG GAGCAGGAGG TGGAGGCCGG 2950

GGTCGAGGAG GCAGTGGAGG CCGGGGTCGA GGAGGTAGTG GAGGCCGGGG 3000

50 TCGAGGAGGT AGTGGAGGCC GCCGGGGTAG AGGACGTGAA AGAGCCAGGG 3050

55 GGGGAAGTCG TGAAAGAGCC AGGGGGAGAG GTCGTGGACG TGGAGAAAAG 3100

AGGCCCAGGA GTCCAGTAG TCAGTCATCA TCATCCGGGT CTCCACCGCG 3150

5 CAGGCCCCCT CCAGGTAGAA GGCCATTTT CCACCCTGTA GGGGAAGCCG 3200

ATTATTTTGA ATACCACCAA GAAGGTGGCC CAGATGGTGA GCCTGACGTG 3250

10 CCCCCGGGAG CGATAGAGCA GGGCCCCGCA GATGACCCAG GAGAAGGCC 3300

AAGCACTGGA CCCCCGGGTC AGGGTGATGG AGGCAGGCGC AAAAAAGGAG 3350

15 GGTGGTTTGG AAAGCATCGT GGTCAAGGAG GTTCCAACCC GAAATTTGAG 3400

AACATTGCAG AAGGTTTAAG AGCTCTCCTG GCTAGGAGTC ACGTAGAAAG 3450

20 GACTACCGAC GAAGGAACCT GGGTCGCCGG TGTGTTGTA TATGGAGGTA 3500

GTAAGACCTC CCTTTACAAC CTAAGGCGAG GAACTGCCCT TGCTATTCCA 3550

CAATGTCGTC TTACACCATT GAGTCGTCTC CCCTTTGGAA TGGCCCCTGG 3600

30 ACCCGGCCCA CAACCTGGCC CGCTAAGGGA GTCCATTGTC TGTTATTCA 3650

TGGTCTTTTT ACAAACTCAT ATATTGCTG AGGTTTTGAA GGATGCGATT 3700

35 AAGGACCTTG TTATGACAAA GCCCGCTCCT ACCTGCAATA TCAGGGTGAC 3750

TGTGTGCAGC TTTGACGATG GAGTAGATT GCCTCCCTGG TTTCCACCTA 3800

TGGTGGAAGG GGCTGCCGCG GAGGGTGATG ACGGAGATGA CGGAGATGAA 3850

45 GGAGGTGATG GAGATGAGGG TGAGGAAGGG CAGGAGTGAT GTAACCTGTT 3900

AGGAGACGCC CTCAATCGTA TTAAAGCCG TGTATTCCCC CGCACTAAAG 3950

50 AATAAATCCC CAGTAGACAT CATGCGTGCT GTTGGTGTAT TTCTGGCCAT 4000

55 CTGTCTTGTC ACCATTTTCG TCCTCCCAAC ATGGGGCAAT TGGGCATACC 4050

CATGTTGTCA CGTCACTCAG CTCGCGCTC AACACCTTCT CGCGTTGGAA 4100

5 AACATTAGCG ACATTTACCT GGTGAGCAAT CAGACATGCG ACGGCTTTAG 4150

CCTGGCCTCC TTAAATTAC CTAAGAATGG GAGCAACCAG CATGCAGGAA 4200

10 AAGGACAAGC AGCGAAAATT CACGCCCCCT TGGGAGGTGG CGGCATATGC 4250

AAAGGATAGC ACTCCCACTC TACTACTGGG TATCATATGC TGA CTGTATA 4300

15 TGCATGAGGA TAGCATATGC TACCCGGATA CAGATTAGGA TAGCATATAC 4350

TACCCAGATA TAGATTAGGA TAGCATATGC TACCCAGATA TAGATTAGGA 4400

20 TAGCCTATGC TACCCAGATA TAAATTAGGA TAGCATATAC TACCCAGATA 4450

25 TAGATTAGGA TAGCATATGC TACCCAGATA TAGATTAGGA TAGCCTATGC 4500

TACCCAGATA TAGATTAGGA TAGCATATGC TACCCAGATA TAGATTAGGA 4550

30 TAGCATATGC TATCCAGATA TTTGGGTAGT ATATGCTACC CAGATATAAA 4600

TTAGGATAGC ATATACTACC CTAATCTCTA TTAGGATAGC ATATGCTACC 4650

35 CGGATACAGA TTAGGATAGC ATATACTACC CAGATATAGA TTAGGATAGC 4700

40 ATATGCTACC CAGATATAGA TTAGGATAGC CTATGCTACC CAGATATAAA 4750

TTAGGATAGC ATATACTACC CAGATATAGA TTAGGATAGC ATATGCTACC 4800

45 CAGATATAGA TTAGGATAGC CTATGCTACC CAGATATAGA TTAGGATAGC 4850

ATATGCTATC CAGATATTTG GGTAGTATAT GCTACCCATG GCAACATTAG 4900

50 CCCACCGTGC TCTCAGCGAC CTCGTGAATA TGAGGACCAA CAACCCTGTG 4950

55 CTTGGCGCTC AGGCGCAAGT GTGTGTAATT TGTCTCCAG ATCGCAGCAA 5000



TCGCGCCCCCT ATCTTGGCCCC GCCCACCTAC TTATGCAGGT ATTCCCCGGG 5050

5 GTGCCATTAG TGGTTTTGTG GGCAAGTGGT TTGACCGCAG TGGTTAGCGG 5100

GGTTACAATC AGCCAAGTTA TTACACCCTT ATTTTACAGT CCAAACCCGC 5150

10 AGGGCGGCGT GTGGGGGCTG ACGCGTGCCC CCACTCCACA ATTTCAAAAA 5200

AAAGAGTGGC CACTTGTCTT TGTTTATGGG CCCCATTGGC GTGGAGCCCC 5250

15 GTTTAATTTT CGGGGGTGTT AGAGACAACC AGTGGAGTCC GCTGCTGTCTG 5300

GCGTCCACTC TCTTCCCCCT TGTTACAAAT AGAGTGTAAC AACATGGTTC 5350

20 ACCTGTCTTG GTCCCTGCCT GGGACACATC TTAATAACCC CAGTATCATA 5400

25 TTGCACTAGG ATTATGTGTT GCCCATAGCC ATAAATTCGT GTGAGATGGA 5450

CATCCAGTCT TTACGGCTTG TCCCCACCCC ATGGATTCTT ATTGTTAAAG 5500

30 ATATTCAGAA TGTTTCATTC CTACACTAGT ATTTATTGCC CAAGGGGTTT 5550

GTGAGGGTTA TATTGGTGTC ATAGCACAAT GCCACCACTG AACCCCCCGT 5600

35 CCAAATTTTA TTCTGGGGGC GTCACCTGAA ACCTTGTTTT CGAGCACCTC 5650

40 ACATACACCT TACTGTTTAC AACTCAGCAG TTATTCTATT AGCTAAACGA 5700

AGGAGAATGA AGAAGCAGGC GAAGATTCAG GAGAGTTCAC TGCCCGCTCC 5750

45 TTGATCTTCA GCCACTGCCC TTGTGACTAA AATGGTTCAC TACCCTCGTG 5800

GAATCCTGAC CCCATGTAAA TAAAACCGTG ACAGCTCATG GGGTGGGAGA 5850

50 TATCGCTGTT CCTTAGGACC CTTTACTTAA CCCTAATTCG ATAGCATATG 5900

55 CTCCCCGTTG GGTAACATAT GCTATTGAAT TAGGGTTAGT CTGGATAGTA 5950

TATACTACTA CCCGGAAGC ATATGCTACC CGTTTAGGGT TAACAAGGGG 6000

5 GCCTTATAAA CACTATTGCT AATGCCCTCT TGAGGGTCCG CTTATCGGTA 6050

GCTACACAGG CCCCTCTGAT TGACGTTGGT GTAGCCTCCC GTAGTCTTCC 6100

10 TGGGCCCCCTG GGAGGTACAT GTCCCCCAGC ATTGGTGTA GAGCTTCAGC 6150

CAAGAGTTAC ACATAAAGGC AATGTTGTGT TGCAGTCCAC AGACTGCAAA 6200

15 GTCTGCTCCA GGATGAAAGC CACTCAGTGT TGGCAAATGT GCACATCCAT 6250

TTATAAGGAT GTCAACTACA GTCAGAGAAC CCCTTTGTGT TTGGTCCCCC 6300

20 CCCGTGTCAC ATGTGGAACA GGGCCCAAGT GGCAAGTTGT ACCAACCAAC 6350

TGAAGGGATT ACATGCACTG CCCGTGACCA ATACAAAACA AAAGCGCTCC 6400

TCGTACCAGC GAAGAAGGGG CAGAGATGCC GTAGTCAGGT TTAGTTCGTC 6450

30 CGGCGGCGGG GGATCCGCCA GAAATCCGCG CGGTGGTTTT TGGGGGTCGG 6500

GGGTGTTTGG CAGCCACAGA CGCCCGGTGT TCGTGTCGCG CCAGTACATG 6550

35 CGGTCCATGC CCAGGCCATC CAAAACCAT GGGTCTGTCT GCTCAGTCCA 6600

GTCGTGGACC TGACCCACG CAACGCCCAA AGAATAACC CCCACGAACC 6650

ATAAACCATT CCCCATGGGG GACCCCGTCC CTAACCCACG GGGCCCGTGG 6700

45 CTATGGCGGG CTTGCCGCCC CGACGTGGC TGCGAGCCCT GGGCCTTCAC 6750

CCGAAC TTGG GGGTTGGGGT GGGGAAAAGG AAGAAACGCG GCGTATTGG 6800

50 CCCCAATGGG GTCTCGGTGG GGTATCGACA GAGTGCCAGC CCTGGGACCG 6850

55 AACCCCGCGT TTATGAACAA ACGACCCAAC ACCCGTGCCT TTTATTCTGT 6900

CTTTTATTG CCGTCATAGC GCGGGTTCCT TCCGGTATTG TCTCCTTCCG 6950

5 TGTTTCAGTT AGCCTCCCCC ATCTCCCGG GTGGGCGAAG AACTCCAGCA 7000

TGAGATCCCC GCGCTGGAGG ATCATCCAGC CGGCGTCCCG GAAAACGATT 7050

10 CCGAAGCCCA ACCTTTCATA GAAGGCGGCG GTGGAATCGA AATCTCGTGA 7100

TGGCAGGTTG GCGCTCGCTT GGTGCGTCAT TTCGAACCCC AGAGTCCCGC 7150

15 TCAGAAGAAC TCGTCAAGAA GCGGATAGAA GCGGATGCGC TCGGAATCGG 7200

GAGCGGCGAT ACCGTAAAGC ACGAGGAAGC GGTCAGCCCA TTCGCCGCCA 7250

20 AGCTCTTCAG CAATATCACG GGTAGCCAAC GCTATGTCCT GATAGCGGTC 7300

25 CGCCACACCC AGCCGGCCAC AGTCGATGAA TCCAGAAAAG CGGCCATTTT 7350

CCACCATGAT ATTCGGCAAG CAGGCATCGC CATGGGTCAC GACGAGATCC 7400

30 TCGCCGTCGG GCATGCGCGC CTTGAGCCTG GCGAACAGTT CGGCTGGCGC 7450

GAGCCCCTGA TGCTCTTCGT CCAGATCATC CTGATCGACA AGACCGGCTT 7500

35 CCATCCGAGT ACGTGCTCGC TCGATGCGAT GTTTCGCTTG GTGGTCGAAT 7550

40 GGGCAGGTAG CCGGATCAAG CGTATGCAGC CGCCGCATTG CATCAGCCAT 7600

GATGGATACT TTCTCGGCAG GAGCAAGGTG AGATGACAGG AGATCCTGCC 7650

45 CCGGCACTTC GCGCAATAGC AGCCAGTCCC TTCCCGCTTC AGTGACAACG 7700

TCGAGCACAG CTGCGCAAGG AACGCCCGTC GTGGCCAGCC ACGATAGCCG 7750

50 CGCTGCCTCG TCCTGCAGTT CATTCAAGGC ACCGGACAGG TCGGTCTTGA 7800

55 CAAAAAGAAC CGGGCGCCCC TGCGCTGACA GCCGGAACAC GCGGGCATCA 7850

GAGCAGCCGA TTGTCTGTTG TGCCCACTCA TAGCCGAATA GCCTCTCCAC 7900

5 CCAAGCGGCC GGAGAACCTG CGTGCAATCC ATCTTGTTCA ATCATGCGAA 7950

ACGATCCTCA TCCTGCTCTT TGATCAGATC TGCGGCACGC TGTTGACGCT 8000

10 GTTAAGCGGG TCGCTGCAGG GTCGCTCGGT GTTCGAGGCC ACACGCGTCA 8050

CCTTAATATG CGAAGTGGAC CTGGGACCGC GCCGCCCCGA CTGCATCTGC 8100

15 GTGTTTGAAT TCATCAAAGC AACCATAGTA CGCGCCCTGT AGCGGCGCAT 8150

TAAGCGCGGC GGGTGTGGTG GTTACGCGCA GCGTGACCGC TACACTTGCC 8200

20 AGCGCCCTAG CGCCCGCTCC TTTGCTTTC TTCCCTTCTT TTCTCGCCAC 8250

25 GTTCGCGGC TTTCCCGTC AAGCTCTAAA TCGGGGGCTC CCTTAGGGT 8300

TCCGATTAG TGCCTTACG CACCTCGACC CCAAAAACT TGATTGGGT 8350

30 GATGGTTCAC GTAGTGGGCC ATCGCCCTGA TAGACGGTTT TTCGCCCTT 8400

GACGTTGGAG TCCACGTTCT TTAATAGTGG ACTCTTGTTT CAACTGGAA 8450

35 CAACACTCAA CCTATCTCG GGCTATTCTT TTGATTATA AGGGATTTG 8500

40 CCGATTTCGG CCTATTGGT AAAAATGAG CTGATTAAAC AAAAATTAA 8550

CGCGAATTTT AACAAAATAT TAACGTTTAC AATTTTATGG TGCAGGCCTC 8600

45 GTGATACGCC TATTTTATA GGTAAATGTC ATGATAATAA TGGTTTCTTA 8650

GACGTCAGGT GGCACTTTTT GGGGAAATGT GCGCGGAACC CCTATTGTT 8700

50 TATTTTCTA AATACATTCA AATATGTATC CGCTCATGAG ACAATAACCC 8750

55 TGATAAATGC TTCAATAATA TTGAAAAGG AAGAGTATGA GTATTCAACA 8800

TTTCCGTGTC GCCCTTATTC CCTTTTGTGC GGCATTTTGC CTTCTGTITT 8850

5 TTGCTCACCC AGAAACGCTG GTGAAAGTAA AAGATGCTGA AGATCAGTTG 8900

GGTGCACGAG TGGGTTACAT CGAACTGGAT CTCAACAGCG GTAAGATCCT 8950

10 TGAGAGTTTT CGCCCCGAAG AACGTTTTCC AATGATGAGC ACTTTTAAAG 9000

TTCTGCTATG TGGCGCGGTA TTATCCCGTG ATGACGCCGG GCAAGAGCAA 9050

15 CTCGGTCGCC GCATACACTA TTCTCAGAAT GACTTGGTTG AGTACTCACC 9100

AGTCACAGAA AAGCATCTTA CGGATGGCAT GACAGTAAGA GAATTATGCA 9150

20 GTGCTGCCAT AACCATGAGT GATAAACTG CGGCCAACTT ACTTCTGACA 9200

ACGATCGGAG GACCGAAGGA GCTAACCGCT TTTTGCACA ACATGGGGGA 9250

25 TCATGTAAT CGCCTTGATC GTTGGGAACC GGAGCTGAAT GAAGCCATAC 9300

30 CAAACGACGA GCGTGACACC ACGATGCCAG CAGCAATGGC AACAACTTG 9350

CGCAAATAT TAACTGGCGA ACTACTTACT CTAGCTTCCC GGCAACAATT 9400

35 AATAGACTGG ATGGAGGCGG ATAAAGTTGC AGGACCACTT CTGCGCTCGG 9450

40 CCGTCCGGC TGGCTGTTT ATTGCTGATA AATCTGGAGC CGGTGAGCGT 9500

GGGTCTCGCG GTATCATTGC AGCACTGGGG CCAGATGGTA AGCCCTCCCG 9550

45 TATCGTAGTT ATCTACAGCA CGGGGAGTCA GGCAACTATG GATGAACGAA 9600

ATAGACAGAT CGCTGAGATA GGTGCCTCAC TGATTAAGCA TTGGTAACTG 9650

50 TCAGACCAAG TTTACTCATA TATACTTTAG ATTGATTTAA AACTTCATT 9700

55 TTAATTTAAA AGGATCTAGG TGAAGATCCT TTTTGATAAT CTCATGACCA 9750

AAATCCCTTA ACGTGAGTTT TCGTTCCACT GAGCGTCAGA CCCCCTAGAA 9800

5 AAGATCAAAG GATCTTCTTG AGATCCTTTT TTTCTGCGCG TAATCTGCTG 9850

CTTGCAAACA AAAAAACCAC CGCTACCAGC GGTGGTTTGT TTGCCGGATC 9900

10 AAGAGCTACC AACTCTTTTT CCGAAGGTAA CTGGCTTCAG CAGAGCGCAG 9950

ATACCAAATA CTGTCCTTCT AGTGTAGCCG TAGTTAGGCC ACCACTTCAA 10000

15 GAACTCTGTA GCACCGCCTA CATACTCGC TCTGCTAATC CTGTTACCAG 10050

TGGCTGCTGC CAGTGGCGAT AAGTCGTGTC TTACCGGGTT GGACTCAAGA 10100

20 CGATAGTTAC CGGATAAGGC GCAGCGGTCG GGCTGAACGG GGGGTTCTGT 10150

25 CACACAGCCC AGCTTGGAGC GAACGACCTA CACCGAACTG AGATACCTAC 10200

AGCGTGAGCA TTGAGAAAGC GCCACGCTTC CCGAAGGGAG AAAGGCGGAC 10250

30 AGGTATCCGG TAAGCGGCAG GGTCCGAACA GGAGAGCGCA CGAGGGAGCT 10300

TCCAGGGGGA AACGCCTGGT ATCTTTATAG TCCTGTCGGG TTTCGCCACC 10350

35 TCTGACTGA GCGTCGATTT TTGTGATGCT CGTCAGGGGG GCGGAGCCTA 10400

40 TGGAAAAACG CCAGCTGGCA CGACAGGTTT CCCGACTGGA AAGCGGGCAG 10450

TGAGCGCAAC GCAATTAATG TGAGTTACCT CACTCATTAG GCACCCAGG 10500

45 CTTTACACTT TATGCTTCCG GCTCGTATGT TGTGTGGAAT TGTGAGCGGA 10550

TAACAATTC ACACAGGAAA CAGCTATGAC CATGATTACG AATTAA 10596

50

(2) INFORMATION FOR SEQ ID NO:16:

55 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 51 bases

(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ATGAAGGCCC CCGCTGTGCT TGCACCTGGC ATCCTCGTGC TCCTGTTTAC 50

10

C 51

15 (2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 56 bases  
(B) TYPE: nucleic acid  
20 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

25

CACTAGTTAG GATGGGGGAC ATGTCTGTCA GAGGATACTG CACTTGTCGG 50

CATGAA 56

30

(2) INFORMATION FOR SEQ ID NO:18:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
40 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TAGTACTAGC ACTATGATGT CT 22

45

(2) INFORMATION FOR SEQ ID NO:19:

50 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
55 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TTTACTTCTT GACGGTCCAA AG 22

5

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 25 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CAGGGGGAGT TGCAGATTCA GCTGT 25

20

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 45 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AGTTTTGTCTG GTGACCTGAT CATTCTGATC TGGTTGAACT ATTAC 45

35



## Claims:

1. A hepatocyte growth factor (HGF) variant resistant to proteolytic cleavage by enzymes that are capable of in vivo conversion of HGF into its two-chain form.
- 5 2. The variant of claim 1 which is a variant of human HGF (huHGF).
3. A hepatocyte growth factor (HGF) variant stabilized in single-chain form by site directed mutagenesis within a region recognized by an enzyme capable of converting HGF into its two-chain  
10 form.
4. The variant of claim 3 which is capable of binding an HGF receptor.
5. The variant of claim 4 which is a variant of human HGF (huHGF).
- 15 6. The variant of claim 5 having an amino acid alteration at or adjacent to amino acid positions 493, 494, 495 or 496 of the wild-type huHGF amino acid sequence.
7. The variant of claim 6 wherein said alteration is substitution.
- 20 8. The variant of claim 6 wherein said alteration is insertion or deletion.
9. The variant of claim 6 in which amino acid position 494 is occupied by an amino acid other than arginine.
10. The variant of claim 9 wherein said amino acid is selected  
25 from the group consisting of glutamic acid, aspartic acid and alanine.
11. The variant of claim 6 wherein said alteration is the substitution of at least one amino acid at amino acid positions 493-496 of the wild-type hHGF amino acid sequence.
12. The variant of claim 11 having another amino acid  
30 substituted for arginine at amino acid position 494 of wild-type huHGF.
13. The variant of claim 11 having another amino acid substituted for valine at amino acid position 495 of wild-type huHGF.
14. The variant of claim 11 having another amino acid  
35 substituted for valine at amino acid position 496 of wild-type huHGF.
15. The variant of claim 6 retaining substantially full receptor binding affinity of wild-type huHGF.

16. A hepatocyte growth factor (HGF) variant having an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the corresponding wild-type HGF.

5 17. The variant of claim 16 comprising an alteration in a region corresponding to the catalytic site of serine proteases.

18. The variant of claim 16 comprising an alteration at or adjacent to any of positions 534, 673 and 692 of the wild-type human HGF (huHGF) amino acid sequence.

10 19. The variant of claim 18 wherein said alteration is substitution.

20. The variant of claim 19 having another amino acid substituted for glutamine at position 534 of the wild-type huHGF amino acid sequence.

15 21. The variant of claim 20 wherein said amino acid is histidine.

22. The variant of claim 19 having another amino acid substituted for tyrosine at position 673 of the wild-type huHGF amino acid sequence.

20 23. The variant of claim 22 wherein said amino acid is devoid of aromatic and heterocyclic moieties.

24. The variant of claim 23 wherein said amino acid is selected from serine, threonine, asparagine, cysteine, glycine, alanine, and valine.

25 25. The variant of claim 24 wherein said amino acid is serine.

26. The variant of claim 19 having another amino acid substituted for valine at position 692 of the wild-type huHGF amino acid sequence.

30 27. The variant of claim 26 wherein said amino acid is polar.

28. The variant of claim 27 wherein said amino acid is selected from serine, threonine, asparagine and glutamine.

29. The variant of claim 28 wherein said amino acid is serine.

35 30. The variant of claim 24 further comprising the substitution of glutamine at position 534 or valine at position 692 of the wild-type huHGF amino acid sequence.

31. The variant of claim 30 having serine substituted for tyrosine at position 673 of the wild-type huHGF amino acid sequence.
32. The variant of claim 31 having histidine substituted for glutamine at position 534 of the wild-type huHGF amino acid sequence.
- 5 33. The variant of claim 31 having serine substituted for valine at position 692 of the wild-type huHGF amino acid sequence.
34. The variant of claim 33 additionally having histidine substituted for glutamine at position 534 of the wild-type huHGF amino acid sequence.
- 10 35. The variant of any of claims 1-15 having an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the corresponding wild-type HGF.
36. The variant of any of claims 16-34 that is resistant to
- 15 proteolytic cleavage.
37. The variant of any of claims 1-36 that is substantially incapable of HGF receptor activation.
38. The variant of any of claims 1-36 that is substantially devoid of HGF hepatocyte growth stimulating activity.
- 20 39. The variant of any of claims 1-36 having increased receptor binding affinity as compared to wild-type huHGF.
40. The variant of claim 39 wherein the increase in receptor binding affinity is accomplished by an alteration in a receptor-binding domain of the huHGF amino acid sequence.
- 25 41. The variant of claim 40 wherein said alteration is in the huHGF  $\alpha$ -chain.
42. The variant of claim 41 wherein said alteration is within the Kringle 1 domain.
43. The variant of claim 42 wherein said alteration is within
- 30 the patch defined by amino acid positions 159, 161, 195 and 197 of the wild-type huHGF amino acid sequence.
44. The variant of claim 42 wherein said alteration is at amino acid position 173 of wild-type huHGF.
45. The variant of claim 41 wherein said alteration is within
- 35 the hairpin domain, N-terminal of the hairpin domain, or between the hairpin and the Kringle 1 domains of wild-type huHGF.

46. The variant of any of claims 1-45 devoid of functional Kringle 2 domain.
47. The variant of any of claims 1-45 devoid of functional Kringle 3 domain.
- 5 48. The variant of any of claims 1-45 devoid of functional Kringle 4 domain.
49. A nucleotide sequence encoding the variant of any of claims 1-48.
- 10 50. A replicable expression vector containing and capable of expressing in a suitable host cell the nucleotide sequence of claim 49.
51. A host cell transformed with the vector of claim 50.
52. A process comprising culturing the host cells of claim 51 so as to express the nucleic acid encoding the HGF variant.
- 15 53. The process of claim 52 further comprising recovering the variant from the host cell culture.
54. A pharmaceutical composition comprising a variant of any of claims 1-48 in an amount capable of competitive inhibition of the binding of wild-type huHGF to its receptor, in admixture with a
- 20 pharmaceutically acceptable carrier.
55. A method of treating a pathological condition associated with the activation of a huHGF receptor comprising administering to a patient in need the composition of claim 54.




FIG. 1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 4



><Modified RK5 derivative, insert Xho I into Hind III site; PJG 2/89>

<from Cori 86.3.18 fix DHFR acc I

<sequence of CMV enhancer/promoter, from Cell 41, 1985>

T><from pPMLCMV beginning to HindIII, enhancers and promoter>

TCGAGCTCGCCCGACATTGATTA

TTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCC  
ATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCT  
GACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCC  
ATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATT  
ACGGTAAACTGCCCACTGGCAGTACATCAAGTGTATCATATGCCAAGTA  
CGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCC  
CAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATT  
AGTCATCGCTATTACCATGGTGTATGCGGTTTTGGCAGTACATCAATGGGC  
GTGGATAGCGGTTTGACTACGGGGATTTCCAAGTCTCCACCCCATTGAC  
GTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTCCAAAATG  
TCGTAACAACTCCGCCCCATTGACGCAATGGGCGGTAGGCGGTACGGT  
GGGAGGTCTATATAAGCAGAGCTCGTTTGTGAACCG

<Begin RNA>

TCAGATCGCCTGG

AGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATC  
CAGCCTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCA  
AGAGTGACGTAAGTACCGCCTATAGAGTCTATAGGCCACCCCTTGGCT  
T

><sp6 promoter>

<GGCCCCCCCCCTTGGCTT>CGTTAGAACGCGGCTACAATTAATACATAACC

TTATGTATCATACATACGATTTAGGTGACACTATA><sp6 RNA  
start>GAATA<ACATCCACTTTGCCTTTC>

ACATCCACTTTGCCTTTCTCTCC

ACAGGTGTCCACTCCAGGTCCAA<PstI-ClaI converter>CTGCA

> < c l o n i n g  
linker>CCTCGGTTCTATCGATTGAATTCCCCGGGGATCCTCTAGAGTCGACCTGCAGAAGCTT  
GCCTCGAGGCAAGCTT  
GGCCGCCATGGCCC

><sv40 early poly A>AACTTGTTTATTGTCAGCTTATAATGGTT

ACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTTCACTGCATTCTA  
GTTGTGGTTTTGTCCAACTCATCAATGTATCTTATCATGTCT  
GGATCGATCGG

> < s v 4 0  
origin>GAATTAATTCTGGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTA  
GGTACCTTC

TGAGGCGGAAAGAACCAGCT

GTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGC  
AGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGC  
TCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCC  
CCCCTAACTCCGCCCCATCCCGCCCCCTAACTCCGCCCAGTTCCGCCCCATCTCCGCCCCAT  
GGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATTC  
CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAA

><start pUC118>

AAGCTGTTAACAGCTTGGC

ACTGGCCGTCGTTTACACGTCGTGACTGGGAAAACC

CTGGCGTTACCCAACTTAATCGCCTTGACGACATCCCCCCTTCGCCAGCTGGCGTAATA

FIG. 5A

GCGAAGAGGCCCCGACCGATCGCCCTTCCCAACAGTTGCGTAGCCTGAATGGCGAATGGC  
 <start M13>

G CCTGATGCGG

TATTTTCTCC TTACGCATCT GTGCGGTATT TCACACCGCA TA

CGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAAGCGCGGCGGGTG  
 TGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCGCTCCTTTTCG  
 CTTTCTTCCCTTCTTTCTCGCCACGTTTCGCGGCTTCCCCGTCAAGCTCTAAATCGGG  
 GGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATT  
 TGGGTGATGGTTACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGT  
 TGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAACTGGAACAACACTCAACCCTA  
 TCTCGGGCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTTAAAAA  
 ATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTT

TATGGTGCAC TCTCAGTACA

ATCTGCTCTG ATGCCGCATA GTTAAGCCA ACTCC GCTATCGCTA  
 CGTGAAGTGG

TCATGGCTGC GCCCGACAC CCGCCAACAC CCGCTGACGC GCCCTGACGG  
 GCTTGTCTGC

TCCCGGCATC CGCTTACAGA CAAGCTGTGA CCGTCTCCGG GAGCTGCATG  
 TGTCAGAGGT

TTTCAACGTC ATCACCAGAA CGCGCGAGGC AG

TATTC

< Hinc II (2271) to GTCATC>

< Pst I (1973) to CTGCTG>

< Acc I (183) delete 6 bp>

<Arbitrarily change EcoRI (1) to GAATAC>

<pUCx 83.11.25 sequence not fully known>

TTGAAGACGA AAGGGCCTCG TGATACGCCT ATTTTATAG  
 GTTAATGTCA TGATAATAAT GGTTCCTTAG ACGTCAGGTG GCACCTTTTCG  
 GGGAAATGTG  
 CGCGGAACCC CTATTGTTT ATTTTCTAA ATACATTCAA ATATGTATCC  
 GCTCATGAGA  
 CAATAACCCT GATAAATGCT TCAATAATAT TGAAAAAGGA AGAGTATGAG  
 TATTCAACAT  
 TTCCGTGTGC CCCTTATTCC CTTTTTTGCG GCATTTTGCC TTCCTGTTTT  
 TGCTCACCCA  
 GAAACGCTGG TGAAAGTAAA AGATGCTGAA GATCAGTTGG GTGCACGAGT  
 GGGTTACATC  
 GAACTGGATC TCAACAGCGG TAAGATCCTT GAGAGTTTTTC GCGCGAAGA  
 ACGTTTTCCA  
 ATGATGAGCA CTTTTAAAGT TCTGCTATGT GCGCGGTAT TATCCCGTGA  
 TGACGCCGGG  
 CAAGAGCAAC TCGGTCGCGG CATACTAT TCTCAGAATG ACTTGGTTGA  
 GTACTACCA  
 GTCACAGAAA AGCATCTTAC GGATGGCATG ACAGTAAGAG AATTATGCAG  
 TGCTGCCATA  
 ACCATGAGTG ATAACACTGC GGCCAACTTA CTTCTGACAA CGATCGGAGG  
 ACCGAAGGAG  
 CTAACCGCTT TTTTGCACAA CATGGGGGAT CATGTAATC GCCTTGATCG  
 TTGGGAACCG  
 GAGCTGAATG AAGCCATACC AAACGACGAG CGTGACACCA CGATGCCAGC  
 AGCAATGGCA  
 ACAACGTTGC GCAAATATT AACTGGCGAA CTACTTACTC TAGCTTCCCG

FIG. 5B

GCAACAATTA  
 ATAGACTGGA TGGAGGCGGA TAAAGTTGCA GGACCACTTC TCGCCTCGGC  
 CCTTCCGGCT  
 GGCTGGTTTA TTGCTGATAA ATCTGGAGCC GGTGAGCGTG GGTCTCGCGG  
 TATCATTGCA  
 GCACTGGGGC CAGATGGTAA GCCCTCCCGT ATCGTAGTTA TCTACACGAC  
 GGGGAGTCAG  
 GCAACTATGG ATGAACGAAA TAGACAGATC GCTGAGATAG GTGCCTCACT  
 GATTAAGCAT  
 TGGTAACTGT CAGACCAAGT TTACTCATAT ATACTTTAGA TTGATTTAAA  
 ACTTCATTTT  
 TAATTTAAAA GGATCTAGGT GAAGATCCTT TTTGATAATC TCATGACCAA  
 AATCCCTTAA  
 CGTGAGTTT CGTTCCACTG AGCGTCAGAC CCCCTAGAAA AGATCAAAGG  
 ATCTTCTTGA  
 GATCCTTTTT TTCTGCGCGT AATCTGCTGC TTGCAAACAA AAAAACCACC  
 GCTACCAGCG  
 GTGGTTTGTT TGCCGGATCA AGAGCTACCA ACTCTTTTTTC CGAAGGTAAC  
 TGGCTTCAGC  
 AGAGCGCAGA TACCAAATAC TGTCTTCTA GTGTAGCCGT AGTTAGGCCA  
 CCACTTCAAG  
 AACTCTGTAG CACCGCCTAC ATACCTCGCT CTGCTAATCC TGTTACCAGT  
 GGCTGCTGCC  
 AGTGGCGATA AGTCGTGTCT TACCGGGTTG GACTCAAGAC GATAGTTACC  
 GGATAAGGCG  
 CAGCGGTCGG GCTGAACGGG GGGTTCGTGC ACACAGCCCA GCTTGGAGCG  
 AACGACCTAC  
 ACCGAACTGA GATACCTACA GCGTGAGCAT TGAGAAAGCG CCACGCTTCC  
 CGAAGGGAGA  
 AAGGCGGACA GGTATCCGGT AAGCGGCAGG GTCGGAACAG GAGAGCGCAC  
 GAGGGAGCTT  
 CCAGGGGGAA ACGCCTGGTA TCTTTATAGT CCTGTCGGGT TTCGCCACCT  
 CTGACTTGAG  
 CGTCGATTTT TGTGATGCTC GTCAGGGGGG CGGAGCCTAT GGAAAAACGC  
 CAGCAACGCG  
 GCCTTTTTAC GGTTCCTGGC CTTTTGCTGG CCTTTTGCTC ACATGTTCTT  
 TCCTGCGTTA  
 TCCCCTGATT CTGTGGATAA CCGTATTACC GCCTTTGAGT GAGCTGATAC  
 CGCTCGCCGC  
 AGCCGAACGA CCGAGCGCAG CGAGTCAGTG AGCGAGGAAG CGGAAGAGC  
 <end M13>  
 GCCCAATACGCA  
 ACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATCCAGCTGGCAGCAGGTTTCCCGA  
 CTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTACCTCACTCATTAGGCACC  
 CCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACA  
 ATTCACACAGGAAACAGCTATGACCATGATTAC  
 GAATTAA

FIG.5C

><pCIS.EBON  
 >< assembled by Steve Williams June 1989  
 ><"poison-minus" pRK  
 ><with EBNA-1, oriP, neoR  
 ><polylinker sites: XhoI, HindIII, NotI

><CMV enhancer/promoter

T  
 TCGAGCTCGCCCGACATTGATTA  
 TTG<SpeI>ACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCC  
 ATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCT  
 GACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCC  
 ATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTT  
 ACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTA  
 CGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCC  
 CAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATT  
 AGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGC  
 GTGGATAGCGGTTTGACTCACGGGGATTTCAGTCTCCACCCCATGAC  
 GTCAATGGGAGTTTGTGTTTGGCACCAAATCAACGGGACTTTCACAAATG  
 TCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGGTACGGT  
 GGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG

<Begin RNA>

TCAGATCGCCTGG  
 AGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATC  
 CAGCCTCCGCGCGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCA  
 AGAGTGACGTAAGTACCGCCTATAGAGTCTATAGGCCACCCCTTGCT

T

><sp6 promoter>

<GGCCCACCCCTTGGCTT>CGTTAGAACGCGGCTACAATTAATACATAACC  
 T T A T G T A T C A T A C A C A T A C G A T T T A G G T G A C A C T A T A >< sp 6 RNA  
 start>GAATA<ACATCCACTTTGCCTTTC>

ACATCCACTTTGCCTTTCTCTCC

ACAGGTGTCCACTCCCAGGTCCAA<PstI-ClaI converter>CTGCA

><cloning linker>CCTCGGTTCT  
 ATCGATTCTCGA

<EcoRI/klenow>GAATTAATTC

AAGCTTGCGGCCGAGCTT  
 GGCCGCCATGGCCC

><sv40 early poly A>AACTTGTTTATTGCAGCTTATAATGGTT  
 ACAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTTTCACTGCATTCTA  
 GTTGTGGTTTGTCAAACTCATCAATGTATCTTATCATGTCT  
 GGATCGATCGG

> < s v 4 0  
 origin>GAATTAATTCGGCGCAGCACCATGGCCTGAAATAACCTCTGAAAGAGGAACTTGGTTA

<KpnI>GGTACCTTC

TGAGGCGGAAAGAACCAGCT

GTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGC

AGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGC

FIG. 6A

TCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCC  
 CCCCTAACTCCGCCCATCCCGCCCCCTAACTCCGCCCAGTTCGCCCCATTCTCCGCCCCAT  
 GGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTGAGCTATTC  
 CAGAAGTAGTGAGGAGGCTTTTTTGGAGGCTAGGCTTTTGCAA

<start pUC118>  
 AAGCTGTT<HpaI end from SW1>

><delta 3  
 <PCR primer seq; PCR product was blunted & ligated in> CACGTGAT  
 <this is EcoRV site remnant>

<RI cassette: EBNA-oriP-tk term-NeoR-tk prom>  
 <4913 bp EcoRI-Bam from 220\_2>  
 <EcoRI>  
 GAATTCTCAT  
 GTTTGACAGC TTATCATCGA TA

><EBNA-1>  
 GATCCTCACA GGCCGCACCC AGCTTTTCTT CCGTTGCCCC AGTAGCATCT CTGTCTGGTG  
 ACCTTGAAGA GGAAGAGGAG GGGTCCCGAG AATCCCCATC CCTACCGTCC AGCAAAAAGG  
 GGGACGAGGA ATTTGAGGCC TGGCTTGAGG CTCAGGACGC AAATCTTGAG GATGTTCAGC  
 GGGAGTTTTT CGGGCTGCGA GTAATTGGTG ATGAGGACGA GGATGGTTTC GAGGATGGGG  
 AATTTTCAGA CCTGGATCTG TCTGACAGCG ACCATGAAGG GGATGAGGGT GGGGGGGCTG  
 TTGGAGGGGG CAGGAGTCTG CACTCCCTGT ATTCACTGAG CGTCGTCTAA TAAAGATGTC  
 TATTGATCTC TTTTAGTGTG AATCATGTCT GACGAGGGGC CAGGTACAGG ACCTGGAAAT  
 GGCCTAGGAG AGAAGGGAGA CACATCTGGA CCAGAAGGCT CCGGCGGCAG TGGACCTCAA  
 AGAAGAGGGG GTGATAACCA TGGACGAGGA CGGGGAAGAG GACGAGGACG AGGAGGCGGA  
 AGACCAGGAG CCCC GGCGG CTTAGGATCA GGGCCAAGAC ATAGAGATGG TGTCCGGAGA  
 CCCC AAAAC GTCCAAGTTG CATTGGCTGC AAAGGGACCC ACGGTGGAAC AGGAGCAGGA  
 GCAGGAGCGG GAGGGGCAGG AGCAGGAGGG GCAGGAGCAG GAGGAGGGGC AGGAGCAGGA  
 GGAGGGGCAG GAGGGGCAGG AGGGGCAGGA GGGGCAGGAG CAGGAGGAGG GGCAGGAGCA  
 GGAGGAGGGG CAGGAGGGGC AGGAGGGGCA GGAGCAGGAG GAGGGGCAGG AGCAGGAGGA  
 GGGGCAGGAG GGGCAGGAGC AGGAGGAGGG GCAGGAGGGG CAGGAGGGGC AGGAGCAGGA  
 GGAGGGGCAG GAGCAGGAGG AGGGGCAGGA GGGGCAGGAG CAGGAGGAGG GGCAGGAGGG  
 GCAGGAGGGG CAGGAGCAGG AGGAGGGGCA GGAGCAGGAG GGGCAGGAGG GGCAGGAGGG  
 GCAGGAGCAG GAGGGGCAGG AGCAGGAGGA GGGGCAGGAG GGGCAGGAGG GGCAGGAGGG  
 GGAGGGGCAG GAGCAGGAGG GGCAGGAGCA GGAGGGGCAG GAGCAGGAGG GGCAGGAGGG  
 GCAGGAGCAG GAGGGGCAGG AGGGGCAGGA GCAGGAGGGG CAGGAGGGGC AGGAGCAGGA  
 GGAGGGGCAG GAGGGGCAGG AGCAGGAGGA GGGGCAGGAG GGGCAGGAGC AGGAGGGGCA  
 GGAGGGGCAG GAGCAGGAGG GGCAGGAGGG GCAGGAGCAG GAGGGGCAGG AGGGGCAGGA  
 GCAGGAGGAG GGGCAGGAGC AGGAGGGGCA GGAGCAGGAG GTGGAGGCCG GGGTCGAGGA  
 GGCAGTGGAG GCCGGGGTCG AGGAGGTAGT GGAGGCCGGG GTCGAGGAGG TAGTGGAGGC  
 CGCCGGGGTA GAGGACGTGA AAGAGCCAGG GGGGGAAGTC GTGAAAGAGC CAGGGGGAGA  
 GGTCTGGAC GTGGAGAAAA GAGGCCAGG AGTCCAGTA GTCAGTCATC ATCATCCGGG  
 TCTCCACCGC GCAGGCCCCC TCCAGGTAGA AGGCCATTTT TCCACCCTGT AGGGGAAGCC  
 GATTATTTTG AATACCACCA AGAAGGTGGC CCAGATGGTG AGCCTGACGT GCCCCGGGA  
 GCGATAGAGC AGGGCCCCGC AGATGACCCA GGAGAAGGCC CAAGCACTGG ACCCCGGGGT  
 CAGGGTGATG GAGGCAGGCG CAAAAAGGA GGGTGTTTG GAAAGCATCG TGGTCAAGGA  
 GGTTC AACC CGAAATTTGA GAACATTGCA GAAGGTTTAA GAGCTCTCCT GGCTAGGAGT  
 CACGTAGAAA GGA CTACCGA CGAAGGAACT TGGGTCGCCG GTGTGTTCGT ATATGGAGGT  
 AGTAAGACCT CCCTTTACAA CCTAAGGCGA GGA ACTGCC TGTCTATTCC ACAATGTCGT  
 CTTACACCAT TGAGTCGTCT CCCCTTTGGA ATGGCCCTG GACCCGGCCC ACAACCTGGC  
 CCGCTAAGGG AGTCCATTGT CTGTTATTTT ATGGTCTTTT TACAACTCA TATATTTGCT  
 GAGGTTTTGA AGGATGCGAT TAAGGACCTT GTTATGACAA AGCCCGCTCC TACCTGCAAT

FIG. 6B

```

ATCAGGGTGA CTGTGTGCAG CTTTGACGAT GGAGTAGATT TGCCTCCCTG GTTTCACCT
ATGGTGGAAG GGGCTGCCGC GGAGGGTGAT GACGGAGATG ACGGAGATGA AGGAGGTGAT
GGAGATGAGG GTGAGGAAGG GCAGGAGTGA TGTAACCTGT TAGGAGACGC CCTCAATCGT
ATTAAAAGCC GTGTATTCCC CCGCACTAAA GAATAAATCC CCAGTAGACA TCATGCGTGC
TGTTGGTGTA TTTCTGGCCA TCTGTCTTGT CACCATTTTC GTCCTCCCAA CATGGGGCAA
TTGGGCATAC CCATGTTGTC ACGTCACTCA GCTCCGCGCT CAACACCTTC TCGCGTTGGA
AAACATTAGC GACATTTACC TGGTGAGCAA TCAGACATGC GACGGCTTTA GCCTGGCCTC
CTTAAATTCA CCTAAGAATG GGAGCAACCA
><oriP>GCATGCAGGA AAAGGACAAG CAGCGAAAAT
TCACGCCCCC TTGGGAGGTG GCGGCATATG CAAAGGATAG CACTCCCACT CTACTACTGG
GTATCATATG CTGAC
><family of repeats>
TGTAT ATGCATGAGG ATAGCATATG CTACCCGGAT ACAGATTAGG
ATAGCATATA CTACCCAGAT ATAGATTAGG ATAGCATATG CTACCCAGAT ATAGATTAGG
ATAGCCTATG CTACCCAGAT ATAAATTAGG ATAGCATATA CTACCCAGAT ATAGATTAGG
ATAGCATATG CTACCCAGAT ATAGATTAGG ATAGCCTATG CTACCCAGAT ATAGATTAGG
ATAGCATATG CTACCCAGAT ATAGATTAGG ATAGCATATG CTATCCAGAT ATTTGGGTAG
TATATGCTAC CCAGATATAA ATTAGGATAG CATATACTAC CCTAATCTCT ATTAGGATAG
CATATGCTAC CCGGATACAG ATTAGGATAG CATATACTAC CCAGATATAG ATTAGGATAG
CATATGCTAC CCAGATATAG ATTAGGATAG CCTATGCTAC CCAGATATAA ATTAGGATAG
CATATACTAC CCAGATATAG ATTAGGATAG CATATGCTAC CCAGATATAG ATTAGGATAG
CCTATGCTAC CCAGATATAG ATTAGGATAG CATATGCTAT CCAGATATTT GGGTAGTATA
TGCTACCC
><end family of repeats>
AT GGCAACATTA GCCCACCGTG CTCTCAGCGA CCTCGTGAAT ATGAGGACCA
ACAACCCTGT GCTTGGCGCT CAGGCGCAAG TGTGTGTAAT TTGTCCTCCA GATCGCAGCA
ATCGCGCCCC TATCTTGGCC CGCCCACCTA CTTATGCAGG TATTCCTCCG GGTGCCATTA
GTGGTTTTGT GGGCAAGTGG TTTGACCGCA GTGGTTAGCG GGGTTACAAT CAGCCAAGTT
ATTACACCTT TATTTTACAG TCCAAAACCG CAGGGCGGCG TGTGGGGGCT GACGCGTGCC
CCCACTCCAC AATTTCAAAA AAAAGAGTGG CCACTTGTCT TTGTTTATGG GCCCCATTGG
CGTGGAGCCC CGTTTAATTT TCGGGGGTGT TAGAGACAAC CAGTGGAGTC CGCTGCTGTC
GGCGTCCACT CTCTTTCCCC TTGTTACAAA TAGAGTGTA CAACATGGTT CACCTGTCTT
GGTCCCTGCC TGGGACACAT CTTAATAACC CCAGTATCAT ATTGCATAG GATTATGTGT
TGCCCATAGC CATAAATTCG TGTGAGATGG ACATCCAGTC TTTACGGCTT GTCCCCACCC
CATGGATTTT TATTGTTAAA GATATTCAGA ATGTTTCATT CCTACACTAG TATTTATTGC
CCAAGGGGTT TGTGAGGGTT ATATTGGTGT CATAGCACAA TGCCACCACT GAACCCCCCG
TCCAAATTTT ATTCTGGGGG CGTCACCTGA AACCTTGTTT TCGAGCACCT CACATACACC
TTACTGTTCA CAACTCAGCA GTTATTCTAT TAGCTAAACG AAGGAGAATG AAGAAGCAGG
CGAAGATTCA GGAGAGTTCA CTGCCCCTC CTTGATCTTC AGCCACTGCC CTTGTGACTA
AAATGGTTCA CTACCCTCGT GGAATCCTGA CCCCATGTAA ATAAAACCGT GACAGCTCAT
GGGGTGGGAG ATATCGCTGT TCCTTA
><dyad region>GGAC CCTTTTACTA ACCCTAATTC GATAGCATAT
GCTTCCCGTT GGGTAACATA TGCTATTGAA TTAGGGTTAG TCTGGATAGT ATATACTACT
ACCCGGGAAG CATATGCTA
><end dyad>C CCGTTTAGGG TTAACAAGGG GGCCTTATAA ACACTATTGC
TAATGCCCTC TTGAGGGTCC GCTTATCGGT AGCTACACAG GCCCCTCTGA TTGACGTTGG
TGTAGCCTCC CGTAGTCTTC CTGGGCCCCCT GGGAGGTACA TGTCCCCCAG CATTGGTGTA
AGAGCTTCAG CCAAGAGTTA CACATAAAGG CAATGTTGTG TTGCAGTCCA CAGACTGCAA
AGTCTGCTCC AGGATGAAAG CCACTCAGTG TTGGCAAATG TGCACATCCA TTTATAAGGA
TGTCAACTAC AGTCAGAGAA CCCCTTTGTG TTTGGTCCCC CCCCCTGTCA CATGTGGAAC
AGGGCCCAGT TGGCAAGTTG TACCAACCAA CTGAAGGGAT TACATGCACT GCCCC
><end oriP>
><HSV TK TERM 3'END>TGACC
AATACAAAAC AAAAGCGCTC CTCGTACCAG CGAAGAAGGG GCAGAGATGC CGTAGTCAGG

```

FIG. 6C

TTTAGTTCGT CCGGCGGC  
 ><pUC12 SmaI-HaeIII polylinker>  
 GG G<Bam site is next>

<1.65 kb Bam-EcoRI frag from pkan2.pcr.bam>  
 GGATCC

><Bam site made by PCR>  
 GCCAGAAATCCGCGCGGTGGT TTTTGGGGGTCGG  
 GGGTGT TTTGGCAGCCACAGACGCCCCGTTGTCGTGTCGCGCCAGTACATGCGGTCCATGC  
 CCAGGCCATCCAAAACCATGGGTCTGTCTGCTCAGTCCAGTCGTGGACCTGACCCACG  
 CAACGCCCAAAAGAATAACCCCCACGAACCATAAACCATTTCCCATGGGGGACCCCGTCC  
 CTAACCCACGGGGCCCGTGGCTATGGCGGGCTTGCCGCCCCGACGTTGGCTGCGAGCCCT  
 GGGCCTTCACCCGAAC TTGGGGGTGGGGTGGGGAAAAGGAAGAAACGCGGGCGTATTGG  
 CCCC AATGGGGTCTCGGTGGGGTATCGACAGAGTGCCAGCCCTGGGACCGAACCCCGCGT  
 TTATGAACAAACGACCCAACCCCGTGCGT TTTTATTCTGTCTTTTATTGCCGTCATAGC  
 GCGGGTTCCTTCCGGTATTGTCTCCTTCCGTGTTTCAGTTAGCCTCCCCCATCT  
 <HSV1 tk terminator SmaI>

<following is EcoRI - SmaI from pKan2, rc>  
 ><tn5 neomycin phosphotransferase gene>  
 <BglII-Sma, rc>

<SmaI, AvaI>CCCGGGGTGGGCGAAGAACTCCAGCATGAGATCCCCGCGCT  
 GGAGGATCATCCAGCCGGCGTCCCGGAAAACGATTCCGAAGCCCAACCTTTTCATAGAAGG  
 CGGCGGTGGAATCGAAATCTCGTGATGGCAGGTTGGGCGTCGCTTGGTCGGTCATTTCTGA  
 ACCCCAGAGTCCCGCTCAGAAGAACTCGTCAAGAAGGCGATAGAAGGCGATGCGCTGCGA  
 ATCGGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTGAGCCCATTCGCCGCCAAGCTC  
 TTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGGTCCGCCACACCCAGCCG  
 GCCACAGTCGATGAATCCAGAAAAGCGGCCATTTTCCACCATGATATTCGGCAAGCAGGC  
 ATCGCCATGGGTACGACGAGATCCTCGCCGTCGGGCATGCGCGCCTTGAGCCTGGCGAA  
 CAGTTCCGGTGGCGCGAGCCCTGATGCTCTTCGTCCAGATCATCCTGATCGACAAGACC  
 GGCTTCCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTCAATGGGCA  
 GGTAGCCGGATCAAGCGTATGCAGCCGCCGCAATTGCATCAGCCATGATGGATACTTTCTC  
 GGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCCGGCACTTCGCCCAATAGCAGCCA  
 GTCCCTTCCCGCTTCAGTGACAACGTCGAGCACAGCTGCGCAAGGAACGCCCGTCGTGGC  
 CAGCCAGATAGCCGCGCTGCGCTCGTCTGAGTTTCAATTCAGGGCACCGGACAGGTCCGT  
 CTTGACAAAAAGAACCGGGCGCCCTGCGCTGACAGCCGGAACACGGCGGCATCAGAGCA  
 GCCGATTGTCTGTTGTGCCAGTCATAGCCGAATAGCCTCTCCACCCAAGCGGCCGGAGA  
 ACCTGCGTGCAATCCATCTTGTTCAATCATGCGAAACGATCCTCATCCTGTCTCTTGATC

><tk promoter>  
 <EcoRI-BglII, rc>  
 <BglII>AGATCTGCGGCACGCTGTTGACGCTGTTAAGCGGGTCGCTGCA  
 GGGTCGCTCGGTGTTTCAGGCCACACGCTCACCTTAATATGCGAAGTGGACCTGGGACC  
 GCGCCGCCCGACTGCATCTGCGTGTTTGAATTC<EcoRI>

<back to SW2 sequence; EcoRV site remnant>  
 A

><M13 ori>  
 TCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAAGCGCGGCGGGTG  
 TGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTTCG

**FIG. 6D**

CTTTCTTCCCTTCCTTTCTCGCCACGTTGCGCGGCTTTCCCGTCAAGCTCTAAATCGGG  
 GGCTCCCTTTAGGGTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATT  
 TGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGT  
 TGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAACTGGAACAACACTCAACCCTA  
 TCTCGGGCTATTCTTTTGATTTATAAGGGATTTGCGGATTTGCGCCTATTGGTTAAAAA  
 ATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTT

TATGGTGCA<ApaLI/blunt>

><delta 2a>

		<Eco0109I/blunt>GGCCTCG		TGATACGCCT
ATTTTTATAG				
GTAAATGTCA	TGATAATAAT	GGTTTCTTAG	ACGTCAGGTG	GCACTTTTCG
GGGAAATGTG				
CGCGGAACCC	CTATTTGTTT	ATTTTTCTAA	ATACATTCAA	ATATGTATCC
GCTCATGAGA				
CAATAACCCT	GATAAATGCT	TCAATAATAT	TGAAAAAGGA	AGAGTATGAG
TATTCACAT				
PTCCGTGTGCG	CCCTTATTCC	CTTTTTTGCG	GCATTTTGCC	TTCCTGTTTT
TGCTCACCCA				
GAAACGCTGG	TGAAAGTAAA	AGATGCTGAA	GATCAGTTGG	GTGCACGAGT
GGGTTACATC				
GAACCTGGATC	TCAACAGCGG	TAAGATCCTT	GAGAGTTTTT	GCCCCGAAGA
ACGTTTTCCA				
ATGATGAGCA	CTTTTAAAGT	TCTGCTATGT	GGCGCGGTAT	TATCCCGTGA
TGACGCCGGG				
CAAGAGCAAC	TCGGTCGCCG	CATACACTAT	TCTCAGAATG	ACTTGGGTGA
GTA CTCACCA				
GTCACAGAAA	AGCATCTTAC	GGATGGCATG	ACAGTAAGAG	AATTATGCAG
TGCTGCCATA				
ACCATGAGTG	ATAACACTGC	GGCCAACTTA	CTTCTGACAA	CGATCGGAGG
ACCGAAGGAG				
CTAACCGCTT	TTTTCACAA	CATGGGGGAT	CATGTAACTC	GCCTTGATCG
TTGGGAACCG				
GAGCTGAATG	AAGCCATACC	AAACGACGAG	CGTGACACCA	CGATGCCAGC
AGCAATGGCA				
ACAACGTTGC	GCAAACCTATT	AACTGGCGAA	CTACTTACTC	TAGCTTCCCG
GCAACAATTA				
ATAGACTGGA	TGGAGGCGGA	TAAAGTTGCA	GGACCACTTC	TGCGCTCGGC
CCTTCCGGCT				
GGCTGGTTTA	TTGCTGATAA	ATCTGGAGCC	GGTGAGCGTG	GGTCTCGCGG
TATCATTGCA				
GCACTGGGGC	CAGATGGTAA	GCCCTCCCGT	ATCGTAGTTA	TCTACACGAC
GGGGAGTCAG				
GCAACTATGG	ATGAACGAAA	TAGACAGATC	GCTGAGATAG	GTGCCTCACT
GATTAAGCAT				
TGGTAACTGT	CAGACCAAGT	TTACTCATAT	ATACTTTAGA	TTGATTTAAA
ACTTCATTTT				
TAATTTAAAA	GGATCTAGGT	GAAGATCCTT	TTTGATAATC	TCATGACCAA
AATCCCTTAA				
CGTGAGTTTT	CGTTCCACTG	AGCGTCAGAC	CCCGTAGAAA	AGATCAAAGG
ATCTTCTTGA				
GATCCTTTTT	TTCTGCGCGT	AATCTGCTGC	TTGCAAACAA	AAAAACCACC

FIG. 6E



```

GCTACCAGCG
  GTGGTTTGTT  TGCCGGATCA  AGAGCTACCA  ACTCTTTTTC  CGAAGGTAAC
TGGCTTCAGC
  AGAGCGCAGA  TACCAAATAC  TGTCCCTCTA  GTGTAGCCGT  AGTTAGGCCA
CCACTTCAAG
  AACTCTGTAG  CACCGCCTAC  ATACCTCGCT  CTGCTAATCC  TGTTACCACT
GGCTGCTGCC
  AGTGGCGATA  AGTCGTGTCT  TACCGGGTTG  GACTCAAGAC  GATAGTTACC
GGATAAGGCG
  CAGCGGTCGG  GCTGAACGGG  GGGTTCGTGC  ACACAGCCCA  GCTTGGAGCG
AACGACCTAC
  ACCGAACTGA  GATACCTACA  GCGTGAGCAT  TGAGAAAGCG  CCACGCTTCC
CGAAGGGAGA
  AAGGCGGACA  GGTATCCGGT  AAGCGGCAGG  GTCGGAACAG  GAGAGCGCAC
GAGGGAGCTT
  CCAGGGGGAA  ACGCCTGGTA  TCTTTATAGT  CCTGTCGGGT  TTCGCCACCT
CTGACTTGAG
  CGTCGATTTT  TGTGATGCTC  GTCAGGGGGG  CGGAGCCTAT  GGAAAAACGC  CAG

```

><delta1.PVU>

<PvuII site introduced by mutagenesis; 228 bp PvuII fragment deleted>

<join to PvuII at 4532 in RK5>

```

CTGGCAGCAGAGGTTTCCCGA
CTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTACCTCACTCATTAGGCACC
CCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACA
ATTTACACAGGAAACAGCTATGACCATGATTAC
GAATTAA

```

**FIG. 6F**

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/04648

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classifications and IPC		
Int.Cl. 5 C12N15/19; C07K13/00; A61K37/02		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	C07K ; C12N ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	WO,A,9 205 184 (THE UNITED STATES OF AMERICA) 2 April 1992 see page 4, line 1 - page 6, line 6 see page 10, line 22 - page 11, line 14 see page 13, line 7 - page 14, line 11 ---	1,2, 37-41, 46-55
A	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 172, no. 1, 15 October 1990, DULUTH, MINNESOTA US pages 321 - 327 TATSUYA, SEKI ET AL. 'Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte' cited in the application see page 322, paragraph 1; figure 2 see page 326, paragraph 1 --- -/-	16,35, 41-43, 49-53
<p><sup>9</sup> Special categories of cited documents:<sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search 27 AUGUST 1993		Date of Mailing of this International Search Report 23. 09. 93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer MONTERO LOPEZ B.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category <sup>a</sup>	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	<p>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 180, no. 2, 31 October 1991, DULUTH, MINNESOTA US pages 1151 - 1158 NOBUYUKI SHIMA ET AL. 'Tumor cytotoxic factor / hepatocyte growth factor from human fibroblasts: cloning of its cDNA, purification and characterization of recombinant protein' see abstract see page 1151, paragraph 1 - page 1152, paragraph 1; figure 1 see page 1154, paragraph 2 - page 1157, paragraph 1</p> <p>---</p>	<p>16, 35, 41-43, 49-53</p>
P, X	<p>EMBO JOURNAL vol. 11, no. 7, July 1992, EYNSHAM, OXFORD GB pages 2503 - 2510 NATHALIE A. LOKKER ET AL. 'Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding' see abstract see page 2505, left column, paragraph 3 - page 2508, right column, paragraph 1</p> <p>---</p>	<p>1-7, 9-12, 15-41, 46-53</p>
P, X	<p>JOURNAL OF BIOLOGICAL CHEMISTRY vol. 267, no. 28, 5 October 1992, BALTIMORE, MD US pages 20114 - 20119 DAIJI NAKA ET AL. 'Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer' see abstract see page 20114, left column, paragraph 2 - right column, paragraph 2 see page 20116, right column, paragraph 2 - page 20118, right column, paragraph 2; figure 4</p> <p>---</p> <p>---/---</p>	<p>1-7, 9, 11, 12, 15-17, 36, 37, 49-53</p>

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	<p>FEBS LETTERS. vol. 311, no. 1, October 1992, AMSTERDAM NL pages 17 - 21 EVA GAK ET AL. 'Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity' see page 17, left column, paragraph 2 - right column, paragraph 1 see page 18, right column, paragraph 2 - page 20, left column, paragraph 1 -----</p>	<p>1-7, 9-12, 15, 36-39, 49-53</p>

## INTERNATIONAL SEARCH REPORT

I. International application No.

PCT/US 93/04648

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 55 is directed to a method of treatment of the human body the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

US 9304648  
SA 74139

27/08/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9205184	02-04-92	AU-A- 8659591	15-04-92
		CA-A- 2091700	15-03-92
-----			